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Abstract
Tuning into Toxins and Channels: 




Advisor: Dr. Sébastien F. Poget
In nature, peptide toxins are an abundant resource, produced both by marine and 
terrestrial organisms. A major target of these peptide toxins is the group of the highly 
important voltage-gated ion channels. Due to their high specificity and affinity, peptide 
toxins have been used for over a decade in discovery and characterization of voltage-
gated ion channels. Although peptide toxins have been extensively characterized 
structurally, the structural characterization of eukaryotic voltage-gated sodium channels 
has seen much less progress, due to their large size and high hydrophobicity. Voltage-
gated sodium channels play crucial roles in many physiological processes, and when 
these processes are disrupted, due to malfunctioning ion channels, they lead to 
diseased states known as channelopathies. It is believed that some channelopathies 
can be corrected through fine tuning of the gating properties of the diseased channels 
through the use of drugs or peptide toxins. If the structural interactions of these peptide 
toxins with their cognate voltage-gated sodium channels can be unraveled, we may be 
able to use them as drugs directly or as lead compounds for the thoughtful design of 
small molecules that exploit these interactions. Here, I have taken the following steps 
towards an increased structural understanding of ion channel-toxin interactions: 
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Firstly, we have shed light on the first high-resolution structure of a novel class of 
peptide toxins known as teretoxins with the determination of the structure of Tv1. Tv1 
was isolated from the terebrid marine snail Terebra variegata in nanogram quantities 
and its sequence determined by direct mass spectrometry sequencing. The peptide 
was chemically synthesized and refolded, and then subjected to solution-state NMR 
experiments. We were able to solve the structure of Tv1 to a resolution 0.74 Å using 2D-
homonuclear/heteronuclear NMR techniques. Although Tv1’s target remains elusive, 
structural features suggest that its natural target is an ion channel.
Voltage-sensor domains of voltage-gated ion channels are responsible for 
sensing changes in the membrane potential of excitable cells and translating this 
information into the various states of the pore (open, closed, inactivated), but the 
mechanism by which these states are transferred from the voltage-sensor domain to the 
channel remains unknown. Here we have expressed a voltage-sensor domain of the 
human cardiac voltage-gated sodium channel. We have demonstrated the ability to 
isotopically label the voltage-sensor domain in a bacterial expression system. 15N-
labeled voltage-sensor domain was subjected to 15N-TROSY experiments to 
demonstrate the feasibility of structural studies. The Voltage-Sensor Domain under 
study produced little to no signal in n-DPC micelles, but marked improvement was 
obtained in a bicelle system. In spite of such improvement, system conformational 
heterogeneity seems to be apparent. We were also able to pull down a toxin from the 
venom of the tarantula Grammastola rosea using immobilized voltage-sensor domain, 
with the potential establishment of a method for the discovery of novel site 3 toxins by 
pull down with NaV1.5.
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Paddle motifs are the target of many gating-modifier toxins and have been shown 
to bind toxins independent of their background (placement into non-native channels) 
and in isolation. Here we present the synthesis (both chemical and biological) and 
characterization of a mammalian 37 residue NaV paddle motif. We subjected an 
isotopically labeled paddle motif of DIV of the human cardiac voltage-gated sodium 
channel (NaV1.5) to various 2D and 3D NMR experiments and assigned 86% of the 
backbone residues. We also recorded NMR spectra of the paddle motif in the presence 
of ApA, a known site-3 gating modifier toxin, which yielded complete loss of NMR signal, 
indicating that an interaction is occurring. Through the establishment of our backbone 
assignments, interactions of known site 3 gating-modifier toxins and NaV1.5 DIV S3-S4 
paddle motif can be characterized, yielding mechanistic insights and knowledge that 
could be used in drug design. 
Peptide toxins and voltage-gated ion channels have been used to unravel the 
secrets of each other for years, and our work continues in that direction. With Tv1 we 
have shown the ability to structurally characterize a peptide toxin using limited 
resources, which will open the door to structurally characterizing toxins thought to be 
restricted due to sample size limitations. With the NaV1.5 VSD and paddle motif of DIV 
we have presented a strategy to express and structurally characterize transmembrane 
fragments of a eukaryotic voltage-gated sodium channel in the absence and presence 
of gating-modifier toxins by NMR spectroscopy. Taken together, the experiments we 
conducted have increased the atomic level knowledge of toxin and eukaryotic voltage-
gated ion channel biology.  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The plasma membrane defines a cellular unit by creating an impermeable barrier 
to hydrophilic molecules between the exterior and the interior of a cell. Ion channels are 
therefore like molecular gate keepers of the cell, allowing or impeding signals into and 
out of the cell. Ion channels are a class of integral membrane proteins and are of 
extreme importance to a diverse array of physiological process such as, but not limited 
to, hormone release (1), propagation of the heart beat (2) and nerve impulses (3). Ion 
channels perform these tasks by maintaining and altering membrane potentials by 
allowing the selective passage of ions across the membranes in which they are 
embedded. Ion channels are divided into subclasses based on their mechanism of 
gating; voltage-gated (4), ligand-gated (5), mechano-gated (6), and temperature gated 
(7). 
1.2 Voltage-gated Ion Channels
Voltage-gated ion channels (VGICs), are important in detecting differences in 
membrane potential and therefore can propagate muscle contractions and action 
potentials in various tissues such as cardiac muscle, smooth muscle, and neurons; 
known as excitable tissues and cells. VGICs consist of two main functional domains - a 
central pore that allows for passage of ions through the membrane, and a voltage-
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sensor domain (VSD) which regulates the different states of the channel (open, closed 
and inactivated) based on the membrane potential. Channels are made of four 
symmetrically arranged subunits (known as domains I-IV (DI-DIV)) - each subunit 
consisting of 6 transmembrane domains (TMs). TMs 1-4 (typically known as S1-S4) 
from each of the subunits form the 4 flanking voltage-sensor domains (VSDs), and TMs 
5 and 6 (S5-S6) from all the subunits form the tetrameric pore domain. In voltage-gated 
K+ channels (Kv), all four domains are identical protein monomers, whereas in 
eukaryotic voltage-gated Na+ and Ca2+ channels (Nav and Cav respectively), the four 
domains are encoded by one protein (Figure 1.1; (8)). The loops between S5 and S6 of 
repeats DI-DIV form the ion selectivity filter conferring ion specificity to the channel 
protein, whereas the intracellular parts of S6 from each domain form an apex or 
aperture known as the gate, which can impede or allow ion flow. The internal gate is 
controlled by the S4-S5 loop, which transfers movements of the VSD due to potential 
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channels are the molecular targets for a wide range
of potent biological toxins, including the gating
modifier toxins that alter the kinetics and voltage
dependence of their activation and inactivation.
This introductory chapter introduces the voltage-
gated ion channels, gives an overview of the
common features of their structure and function,
presents the sodium channel as a primary example
of neurotoxin action on ion channels, and describes
the voltage-sensor trapping model for gating modi-
fier toxin action, which may be a common mechan-
ism of polypeptide toxin action on ion channels.
1.1. Voltage-gated sodium channels
The founding member of the ion channel super-
family in terms of its discovery as a protein is the
voltage-gated sodium channel. These channels are
responsible for the rapid influx of sodium ions that
underlies the rising phase of the action potential in
nerve, muscle, and endocrine cells. Neurotoxin
labeling, purification and functional reconstitution
showed that sodium channels from mammalian
brain contain voltage-sensing and pore-forming
elements in a single protein complex of one principal
a subunit of 220–260 kDa and one or two auxiliary
b subunits of approximately 33–36 kDa (Catterall,
1984, 2000a). The a subunits of sodium channels are
composed of four homologous domains that each
contain six hydrophobic transmembrane segments
(Fig. 1). A membrane-reentrant loop between the
fifth and sixth (S5 and S6) transmembrane segments
forms the narrow extracellular end of the pore while
the S6 segments form the intracellular end (Fig. 1A,
red). The pore is formed in the center of a
pseudosymmetric array of the four domains, and a
single a subunit containing four domains is able to
receive voltage sig als and activate its intrinsic pore.
The channel responds to voltage by virtue of its S4
segments (Fig. 1A, green), which contain repeated
ARTICLE IN PRESS
Fig. 1. The voltage-gated ion channels: A. The different members of the ion channel protein family structurally related to the voltage-
gated ion channels are illustrated as transmembrane folding diagrams in which cylinders represent probable transmembrane alpha helices.
Red, S5–S6 pore-forming segments; green, S4 voltage sensor; and blue, S1–S3 transmembrane segments B. Auxiliary subunits of the
voltage-gated ion channels. The auxiliary subunits of NaV, CaV, and KV channels are illustrated, with cylinders representing predicted
alpha helices of the transmembrane subunits. N-linked carbohydrate chains are indicated by c. The intracellular auxiliary subunits are
illustrated by their predicted three-dimensional structures.
W.A. Catterall et al. / Toxicon 49 (2007) 124–141 125
Figure 1.1: Topology of voltage-gated ion channels. Nav and Cav channels code for domains I-IV in a 
single polypeptide, whereas Kv channels code for each domain as a separate polypeptide chain. Green 
cylinders represent S4 (the voltage-sensor), pink representing S5-6 (the pore forming TMs) and red 
representing the S5-6 linker (selectivity filter). Image from (8).
changes in the membrane to the internal gate, allowing for the opening of the channel 
aperture.
1.3 Voltage-gated Sodium Channels
NaVs were first discovered in 1952 by Hodgkin and Huxley when studying the 
giant squid axon (9). NaVs come in two flavors, bacterial and eukaryotic. Bacterial NaVs 
are more akin to KVs in that they are formed by four identical monomers, whereas the 
eukaryotic NaVs are formed by one protein in a pseudotetrameric fashion. There have 
been studies on only 9 isoforms of eukaryotic NaVs from subfamily 1 (NaV1.1-1.9) 
described to date (10) and on an NaV2 subfamily who's function is not well 
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Figure 1.2: NaV isoform tissue specific expression profile. NaV1.1-1.9 are expressed in various 
tissues from the CNS, PNS, smooth muscle, skeletal muscle, cardiac, and even cancer cells. 
Channelopathies are listed on the right. Image from (12).
characterized showing less than 50% homology to subfamily 1 (11). All NaV isoforms are 
expressed in a tissue specific manner (Figure 1.2; (12)). The nine Nav isoforms can be 
separated into two groups, the tetrodotoxin (TTX) resistant (TTX-R) and the TTX 
sensitive (TTX-S) channels. NaV1.1-1.4, 1.6 and 1.7 are all TTX-S and are affected by 
TTX in the nM concentration range, whereas NaV1.5, NaV1.8, and NaV1.9 are TTX-R 
and affected in the mM range (13). All nine isoforms share greater than 50% amino acid 
sequence homology (Figure 1.3, (13)). In nature, NaVs are found as a ~260 kDa α-
subunit associated with one or more β-subunits (1-4 depending on the tissue). Although 
the NaV α-subunits are enough to conduct Na+ ions across the membrane, β-subunits 
modify the gating kinetics and channel localization (14). NaVs are responsible for the 
rapid upstroke of the action potential (depolarization) in excitable cells initiating and 
propagating the action potentials in neuronal cells, cardiomyocytes and skeletal 
myocytes (Figure 1.4; (10)). Typically NaV channels rapidly inactivate within milliseconds 
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single position in domain I, and they are highly ex-
pressed in heart and dorsal root ganglion neurons (Foz-
zard and Hanck, 1996; Catterall, 2000). Their genes are
located on human chromosome 3p21-24, consistent with
a common evolutionary origin. The isoforms NaV1.4,
expressed primarily in skeletal muscle, and NaV1.6, ex-
pressed primarily in the central nervous system, are set
apart from these other two closely related groups of
sodium channel genes (Fig. 2B). Although their amino
acid sequences are greater than 84% identical to the
group of sodium channels whose genes are located on
chromosome 2 (Fig. 2A), their phylogenetic relationship
is much more distant when analyzed by parsimony com-
parison (Fig. 2B). This distant evolutionary relationship
is consistent with the location of the genes encoding
these two sodium channels on chromosomes 17q23-25
and 12q13, respectively. The chromosome segments car-
rying the sodium channel genes are paralogous seg-
ments that contain many sets of related genes, including
the homeobox gene clusters. These segments were gen-
erated by whole genome duplication events during early
vertebrate evolution (Plummer and Meisler, 1999). The
comparisons of amino acid sequence identity and phylo-
genetic and chromosomal relationships lead to the con-
clusion that all nine members of the sodium channel
family that have been functionally expressed are mem-
bers of a single family of proteins and have arisen from
gene duplications and chromosomal rearrangements rela-
tively recently in evolution. These results contrast with
those for potassium channels and calcium channels, for
which distinct gene families have arisen earlier in evolu-
tion and have been maintained as separate families to the
present (Chandy and Gutman, 1993; Ertel et al., 2000).
In addition to these nine sodium channels that have
been functionally expressed, closely related sodium
channel-like proteins have been cloned from mouse, rat,
and human but have not yet been functionally expressed
(Nax). They are approximately 50% identical to the NaV1
subfamily of channels but more than 80% identical to
each other. They have significant amino acid sequence
differences in the voltage sensors, inactivation gate, and
pore region that are critical for channel function and
have previously been proposed as a distinct subfamily
(George et al., 1992). These atypical sodium channel-like
proteins are expressed in heart, uterus, smooth muscle,
astrocytes, and neurones in the hypothalamus and pe-
ripheral nervous system. Because of their sequence dif-
ferences, it is possible that these channels are not highly
sodium-selective or voltage-gated. Although these pro-
teins have striking differences in amino acid sequence in
highly conserved regions of sodium channels, their
amino acid sequence is greater than 50% identical to
other sodium channels. They are closely related phylo-
genetically to the group of sodium channels on human
chromosome 2q23-24, where their gene is also located
(Goldin et al., 2000). Successful functional expression of
these atypical sodium channel-like proteins and identi-
fication of additionally related sodium channels may
provide evidence for a second sodium channel subfamily.
Four auxiliary subunits of sodium channels have been
defined thus far: NaV!1, NaV!2, NaV!3, and NaV!4 (Cat-
FIG. 2. Amino acid sequence similarity and phylogenetic relationships
of voltage-gated sodium channel " subunits. Phylogenetic relationships
by maximum parsimony analysis of rat sodium channel sequences
Nav1.1–Nav1.9 and Nax. To perform the analysis, the amino acid se-
quences for all isoforms were aligned using Clustal W. The amino acid
sequences in the alignments were then replaced with the published
nucleotide sequences, and the nucleotide sequence alignments were sub-
jected to analysis using the program PAUP*. Divergent portions of the
terminal regions and the cytoplasmic loops between domains I–II and
II–III were excluded from the PAUP* analysis. The tree was rooted by
including the invertebrate sodium channel sequences during the gener-
ation of the tree, although these sequences are not shown in the figure.
TABLE 1
Receptor sites on sodium channels
Receptor Site Toxin or Drug Domains
Neurotoxin receptor Tetrodotoxin IS2–S6, IIS2–S6
site 1 Saxitoxin IIIS2–S6, IVS2–S6
#-Conotoxin
Neurotoxin receptor Veratridine IS6, IVS6
site 2 Batrachotoxin
Grayanotoxin
Neurotoxin receptor "-Scorpion toxins IS5–IS6, IVS3–S4
site 3 Sea anemone toxins IVS5–S6
Neurotoxin receptor
site 4
!-Scorpion toxins IIS1–S2, IIS3–S4





Local anesthetic Local anesthetic drugs IS6, IIIS6, IVS6
receptor site Antiarrhythmic drugs
Antiepileptic drugs
NOMENCLATURE AND RELATIONSHIPS OF VOLTAGE-GATED SODIUM CHANNELS 399
Figure 1.3: NaV amino acid sequence homology. NaV1.1-1.3, and 1.7 are most closely related of all 
the NaVs. Although all NaVs as a whole share greater than 50% sequence homology. Image from (13).
of channel activation (15). This quick inactivation allows for the repetitive firing in 
excitable cells. The function of NaVs is not limited to the initiation and propagation of 
action potentials. They have also been shown to be involved in cellular functions of non-
excitable cells such as phagocytosis, cell motility, and metastasis as reviewed by Black 
et al (16). Due to their diverse and important roles in mammalian physiology, it should 
be no surprise that numerous mutations cause diseased states called channelopathies. 
Mutations (mostly missense, but also less frequently insertion, deletion or nonsense 
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Figure 1.4: Action potentials of NaVs. Black traces represent the membrane potential of a (A) neuron 
and (B) cardiomyocyte during an action potential with the dotted line representing the resting membrane 
potential. Red traces represent the sodium current of the respective cell types during the action 
potential. Circled numbers represent the different states of the NaV during the action potential;  closed 
state, open state, and  inactivated state. Image from (10).
Figure 1 Gating model and contribution of voltage-gated sodium channels to neuronal and cardiac action potential firing. Upper traces
depict a cartoon representation of a whole-cell current clamp recording from a typical neuron (A) or cardiac myocyte (B). Dotted line
indicates the resting membrane potential (Vm). Lower trace is temporally aligned to the upper trace and shows the change in sodium
current (INa) during an action potential. Note a downward deflection of the trace reflects an inward movement of sodium ions into the cell.
(1) At the resting membrane potential VGSCs are closed. A small depolarization of the neuronal membrane potential in response to
sensory input or receptor input depolarizes the neuronal membrane potential to the threshold for VGSC activation (!"50 mV). (2) VGSCs
activate rapidly (!1 ms to peak) allowing the influx of sodium and depolarizing the membrane potential further, forming the upstroke of
the action potential. Note that the peak sodium current correlates with the peak of the action potential. (3) Following activation the
sodium channels inactivate resulting in a decrease in sodium current and repolarization of the neuronal membrane potential, contributing
to the downstroke of the action potential. Recovery from inactivation allows the channels to participate in the next action potential. (C)
Mechanism of voltage sensitive gating of VGSCs. The left channel represents a VGSC in a deactivated (closed) state. A small depolarization
of the membrane potential causes a movement of the positively charged S4 voltage-sensor domain (green) leading to a conformational
change in the protein and opening of the pore (middle channel). Following activation, the pore is rapidly occluded by the inactivation gate,
resulting in inactivation of the sodium channel (right channel).
2586 | Brain 2012: 135; 2585–2612 N. Eijkelkamp et al.






mutations) that lead to channelopathies affect the gating properties of NaVs, leading to 
hyper- or hypo-excitability or elongated sodium currents due to loss of fast inactivation. 
Channelopathies include autism (17), epilepsy (18, 19), cardiac arrhythmias (20), pain 
(21), and more (22). 
1.4 Voltage-Sensor Domains
The VSDs of NaVs are highly conserved throughout nature amongst VGICs, with 
two conserved residues in S1, four in S2, one in S3, and four in S4 even showing a 
coupled conservation amongst these residues (meaning residues of these positions are 
conserved in pairs) (23). The TM S4 contains a positively charged residue at every third 
position, typically arginine or lysine (known as R1, R2, R3, R/K4). This grouping of 
positive charge is what led early researchers to believe that S4 was the voltage-sensor 
of membrane potentials in the VSD. Early on there were three leading models of how 
VSDs translate differences in membrane potential to channel activity as reviewed in 
(24). The first model is known as the helical screw/sliding-helix model. This model 
suggests that the conserved positive charges in S4 are satisfied by negative charges 
elsewhere in the protein, and upon a change in the membrane potential S4 moves 4.5Å 
and rotates 60° per charge moved, allowing the conserved positive charges to make 
new contacts. The second model proposes that the charge transfer of the S4 conserved 
positive charges upon membrane potential change is largely rotational (~180°) and less 
of a translational motion (2-4Å). This model is known as the rocking banana model 
(transporter). The third model (paddle model) puts forth the idea that S3b (a semi 
conservative proline in S3 creates a kink separating the TM into two helices) and S4 
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move as one unit, and complete the gating cycle as one unit, moving outward by 
15-20Å. Latest research indicates a convergence of the helical screw model and paddle 
model (25) (Figure 1.5 (25)). Although all VSDs of KVs and bacterial NaVs contribute 
equally to channel opening, eukaryotic NaV VSDs behave kinetically different, especially 
VSD IV. VSDs I-III have been shown to be kinetically faster in activation than VSD IV 
and are involved in channel opening where as VSD IV is kinetically slower and involved 
in fast-inactivation (26). This has been corroborated through various studies of NaVs 
and the effects that gating-modifier peptide neurotoxins have on them.
1.5 Field of Voltage-Gated Sodium Channel Structures
Most of the structural information of VGICs comes from biochemical studies (24, 
27); whereas actual structures of VGICs are extremely limited, as is the case with 
membrane proteins. The reason for this is their large size and highly hydrophobic and 
flexible nature. Although a few structures of full VGICs have been obtained (mainly by 
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structural models of the voltage-sensing mechanism. Movies
depicting the gating transition from resting to activated states
are available as Supporting Information for Yarov-Yarovoy
et al. (2006a).
Catalytic Mechanism of the Voltage Sensor
Catalysis of S4 Movement
In the sliding-helix model, outward movement of the gating
charg s in the S4 segment proceeds as a stepwise exchange of
ion pair partners, and sequential formation of ion pairs during acti-
vation of NaChBac has been directly demonstrated in disulfide-
locking experiments (DeCaen et al., 2008, 2009). Therefore,
molecular models for each step of the outward movement of the
gating charges can be developed using formation of ion pairs as
a structural constraint (DeCaen et al., 2009; Yarov-Yarovoy et al.,
Biophys. Soc. abstract, 2010). These structural models show the
stepwisemovement of theS4segmentoutward through thegating
porewith sequential formation of ion pairs at each step (Figure 5A).
The results of disulfide-locking experiments indicate that the
R3 gating charge interacts with An1 with the same kinetics and
voltage dependence as R4 interacts with An2, suggesting that
these two ion pair interactions occur simultaneously in the gating
pore (Figure 2D; DeCaen et al., 2009). The structure of the acti-
vated voltage sensor of the KV1.2/KV2.1 chimera contains a short
stretch of the S4 segment in the gating pore in the 310 helical
conformation (Long et al., 2007), and both molecular dynamics
simulations and EPR studies of cysteine-substituted mutants
suggest that the S4 segment forms a segment of 310 helix in
the resting state as well (Chakrapani et al., 2010; Khalili-Araghi
et al., 2010). Placement of this short section of 310 helical confor-
mation in the gating pore allows the dual interaction of R3/An1
and R4/An2 by stretching these two gating charges farther apart
and placing themon exactly the same side of the S4 helix to facil-
itate interaction with An1 and A2 (Figure 5B). Each of the pairs of
gating charges (R1–R2, R2–R3, and R3–R4) is hypothesized to
adopt this stretched 310 helical conformation transiently as the
S4 segment moves outward through the gating pore, allowing
each gating charge to ‘‘stretch out’’ to make its next ion pair
interaction. In the inner and outer vestibules on either side of
the gating pore, the S4 segment may retain its a-helical
conformation and the two ends of the S4 segment may rotate
as it moves outward. Therefore, in this structural version of the
sliding-helix model, the outward movement is not entirely
screw-like; instead, the two ends of the helix move in a screw-
likem nner while the center section, about 9 Å in length, unwinds
to a 310 helix and moves outward linearly. This form of outward
movement diminishes the total rotation of the S4 segment
required for gating charge movement because a section of the
S4 segment remains in the 310 conformation within the gating
pore in the fully activated state and never adopts the a-helical
conformation on the extracellular side of the gating pore. Impor-
tantly, this processive, transient formation of 310 helix also allows
productive ion pair interaction of two gating charges in the gating
pore simultaneously while the intervening hydrophobic residues
point away from An1 and An2 (Figure 5B). Although a 310 helix is
not as stable as an alpha helix, the extent of 310 helix remains the
same in all states in this model so there is no net energetic cost of
breaking alpha helix and making 310 helix. This stretching of the
S4 segment serves an analogous purpose to stretching of cova-
lent bonds in an enzyme catalytic site—provision of a low-energy
pathway between the initial state and the final state. Thus, the
catalytic site of the voltage sensor (i.e., the gating pore) neutral-
izes the gating charges and unwinds and stretches the S4
segment as it moves outward, providing an isoenergetic, hydro-
philic pathway for gating charge translocation across the
focused membrane electric field.
Recent structure-function studies of Shaker K+ channels
provide additional insight into the mechanism of S4 movement
Figure 5. Stepwise Movement of the S4
Segment through the Gating Pore during
Activation of the Bacterial Na+ Channel
NaChBac
(A) Molecular models of the series of ion pair
interactions in the voltage sensor during activa-
tion. For each interaction confirmed by disulfide-
locking experiments, the relevant gating charge
(R1, R2, R3, R4) was constrained to form an ion
pair with An1, and the voltage sensor was
modeled using the Rosetta membrane algorithm
(DeCaen et al., 2008, 2009). Positions of the Cb
atoms of gating charge-carrying arginines in S4
(labeled as R1 through R4 and colored blue) and
negatively charged residues in S2 (labeled D1
and E2 and colored red) are shown in sphere
representation.
(B) Expanded view of gating pore structure with S2
in a-helical conformation and S4 in 310 helical
conformation as predicted by Rosetta modeling.
(C) Gating pore structure as in (B) with the muta-
tions R1Q and R2Q.
(D) Gating pore structure as in (B) with the HypoPP
R2G mutation.
922 Neuron 67, September 23, 2010 ª2010 Elsevier Inc.
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Figure 1.5: Proposed mechanism of action of the NaV voltage-sensor domain. Model of VSD 
activation in NaChBac showing the transition of the voltage-sensor through the gating pore. Breaking and 
formation of salt bridge rearrangements occur as the voltage-sensor moves through the plane of the of 
the membrane and rotates in an extend conformation (310-Helix). Image from (25).
X-ray crystallography), most of them are of KV (28-31) and bacterial NaV channels (32, 
33, 34). All structures to date have shown the VSDs in what is thought to be an 
activated state, this is because there is no membrane potential to increase the 
probability that VSDs will take a non-activated state. There has been one eukaryotic 
NaV structure to date from Electrophorus electricus produced by cryo-electron 
microscopy (cryo-EM) to a very low resolution of 19Å (35) and a chimeric human-
bacterial structure of NaV1.7/NaVAb where the top half of the VSD including its 
extracellular loops of NaV1.7 DIV replaced those of NaVAb (34). There has also been a 
structure of the CaV1.1 in complex with its α2δ, β, and ɣ subunits solved by cryo-EM to 
a resolution of 4.2Å (36). Although cryo-EM is deemed to be the future of structural 
biology (37), it has yet to prove itself in the realm of VGIC structural biology with only 
one high resolution structure produced (35, 36).
One way to aid in producing structures of VGICs would be to implement solution-
state nuclear magnetic resonance spectroscopy (NMR). Using NMR over 
crystallography has its benefits, such as allowing the dynamics of the system under 
study to be probed, and, in contrast to crystallography, little to no modifications are 
needed for increasing the rigidity and stability of the protein. One area where NMR does 
fall short for proteins (especially membrane proteins), is that it is limited by the size of 
the total complex. Due to the size of integral membrane proteins and their membrane 
mimetic, complexes may be too large leading to slow isotropic tumbling and spectral 
line broadening. Since TMs are highly helical, the nuclear environments of different 
residues may also be highly similar, leading to large spectral overlap. One way to 
overcome the size limitations is to study portions or subunits of proteins. In nature, 
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subunits are known to fold independently of each other as opposed to needing all 
subunits present to fold correctly. This has been shown in G-protein coupled receptors 
(GPCRs) as well as VGICs. Fragments of the GPCR Ste2p were co-expressed in yeast, 
and were found to form functional receptors (38), indicating that fragments could 
potentially fold independently of each other into native folds. This has also been proved 
structurally and functionally for VGICs. The MacKinnon group solved the crystal 
structure of KvAP in complex with an antibody fragment (29) as well as both the X-ray 
crystal and solution-state NMR structure of the isolated VSD (28) of the same protein, 
showing that the VSD adopts a similar fold in the intact channel as it does in isolation 
(with the largest deviation between the two structures being an RMSD of 2 Å most likely 
due to distortions induced by co-crystallization with an antibody fragment), and more 
closely resembles the KV1.2-KV2.1 paddle chimera structure(39) with an RMSD of 0.84 
Å. Paddle motifs (a helix-turn-helix motif formed by the S3b and S4 TMs and their 
connecting loop) of NaVs had been placed into KV2.1 replacing its own paddle motif and 
shown to produce functional chimeric channels able to conduct K+ ions upon 
depolarization, and bind NaV gating-modifier toxins (26). Additionally the isolated paddle 
motif from NaV1.2 VSD IV was used in surface plasmon resonance (SPR) studies where 
it was able to bind toxin (40). This justifies the idea of studying isolated paddle motifs 




Peptide neurotoxins are a rich source of natural products (41-43). A prime 
example of the vast richness of peptide neurotoxins is found in the conidae family of 
marine snails; each species can produce upwards of 200 unique peptide toxins, with 
600-700 species and 1,500 -1700 conotoxins described so far (43, 44). Due to their high 
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Figure 1.6: Neurotoxin receptor sites. (A) Neurotoxin receptor sites mapped on to a 2D mammalian 
Nav channel projection shown in various colors. Sites shown are the 6 known sites targeted by 
neurotoxins. (B) Neurotoxin receptor sites mapped on the top-down view of the extracellular side and (C) 
the planar view of the 3D structure of NaVMS. Image from (12).
In summary, we have illustrated the important role of Nav
channels in physiological processes and the consequences of
Nav channel dysfunction, often caused by mutations, leading to
a broad spectrum of diseases associated with various genetic
phenotypes. Because of their key role in neuronal conduction
and muscle contraction, Nav channels have been successfully
targeted for decades by antiepileptic and antiarrhythmic agents
and by local anesthetics. However, currently available Nav
channel modulators are not selective and often suffer from a
limited therapeutic index. Genetic studies in recent years have
pinpointed the role of specific Nav channel subtypes in certain
disease phenotypes and hence identified novel, genetically
validated drug targets. The Nav arena holds promise, and
research investment from academics, biotech, and the
pharmaceutical industry is substantial. The key to success for
any novel therapeutic Nav channel modulators will be increased
potency and selectivity that can improve efficacy and safety
margins relative to existing nonselective treatment options.
■ NATURAL PRODUCTS AND THEIR DERIVATIVES
Throughout history, envenoming by animal and plant toxins
has fascinated humans. By producing toxins that target Nav
channels, venomous animals and poisonous plants exploit the
excitatory and inhibitory action of toxins to incapacitate prey or
defend against predators (Figure 3). Not only do toxins from
scorpions, sea anemones, spiders, cone snails, insects, and plant
extracts serve as important chemical tools for understanding
Nav channel structure, pharmacology and physiology, but they
also provide extraordinary leads for developing novel subtype-
selective agents that have therapeutic potential.
Nonpeptidic Natural Products. Tetrodotoxin, Saxitoxin,
and Zetekitoxin. Tetrodotoxin (TTX, 1, Figures 3A and 6)78
and saxitoxin (STX, 2, Figure 6)79 are neurotoxins which
biology and chemistry have been extensively studied. They
serve as an important reminder of the vital role of natural
products in drug discovery research. TTX and STX are
Figure 4. Location of eight Nav sites identified so far (six sites for different natural toxins plus the local anesthetic and ICA/PF binding sites). (A)
Topology of the human Nav channel α subunit indicating binding sites. (B,C) An extracellular and side view, respectively, of the crystal structure of
bacterial NavMs.
12 Site 1 (red) is formed by the four P-loops and represents the binding site of pore blockers, such as TTX, STX, and μ-conotoxins.
Site 2 (green) is the site for toxins such as BTX, VTD, and antillatoxin, which interact with S6 in DI and DIV. α-ScTxs and Ap-B modulate Nav
channels by binding to Site 3 (cyan) on the extracellular S3−S4 loop in DIV. Site 4 (blue) consists of the extracellular loops S1−S2 and S3−S4 of
DII and constitutes the binding site of β-ScTxs, ProTx-II, and HWTX-II. Site 5 (pink), which comprises S6 of DI and S5 of DIV, has been identified
as the interaction site for ciguatoxins and brevetoxins. Site 6 (orange), via S4 of DIV, binds μO- and δ-conotoxins. Site 7 (purple) is the local
anesthetic binding site in the pore of the channels and consists of amino acid residues in S6 of DI, DIII, and DIV. Site 8 (yellow) is the ICA/PF site
located in the VSD of DIV.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/jm501981g
J. Med. Chem. 2015, 58, 7093−7118
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specificity and affinity, peptide neurotoxins provide powerful tools to study structure and 
function of channels. These neurotoxins can affect permeation through the channel 
pore, and/or gating properties of the voltage-sensor. On eukaryotic sodium channels, 
there are six known neurotoxin receptor sites described to date, and peptide 
neurotoxins are known to target four of those sites (8, 12, 45) (Figure 1.6; (12)). Site 1 is 
known to be the binding site of pore blockers, such as TTX, saxitoxin (STX), and μ-
conotoxins. Sites 2-6 were found to be allosterically coupled - suggesting the 
neurotoxins bound to these sites alter the equilibrium of the various channel states, 
altering conformation of the channel. Neurotoxin binding sites 3 and 4 will be of great 
importance in probing structural information of isolated VSDs of NaVs. Site 3 
neurotoxins bind the paddle motif (S3b-S4 linker region) of DIV, and site 4 neurotoxins 
bind the extracellular loops of DII VSDs. Site 6 neurotoxins may also be beneficial to 
studying VSDs as they interact with the voltage-sensor of domain IV, though it is not 
known if these neurotoxins exclusively bind VSD IV. These neurotoxins come from a 
variety of terrestrial and marine species.
1.6.1 Spider Toxins
Spiders represent the most diverse venomous terrestrial order with over 46,000 
described species curated in the world spider catalog (46). It is believed that a single 
spider venom can contain over 1000 neurotoxins, estimating over 10 million spider 
toxins in nature (42). To date,12 families of spider toxins that target NaVs (NaSpTx 
family 1-12) have been described based on sequence identity and intercysteine 
spacings (47). These spider toxins range in size from 28 to 77 residues in length with 
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disulfide bonds ranging from 3 to 7 depending on the NaSpTx family (47). Families can 
be sorted into two groups depending on what NaV neurotoxin site they bind. NaSpTx 
Families 2, 4, and 12 target receptor site 3, NaSpTx Families 1, 3, 5, 7, and 10 target 
receptor site 4, leaving NaSpTx Family 6 ,9, and 11 with a yet to be determined receptor 
site and NaSpTx Family 8 targeting receptor site 1 (47). Although NaSpTx families 1, 3, 
5, 7, and 10 share the same binding site, their effects are different, with NaSpTx families 
1, 3, and 7 inhibiting channel activation by locking VSD II in the resting state (48-50), 
whereas NaSpTx families 5 and 10 show increased channel activation (51, 52). NaSpTx 
Families 2, 4, and 12 target neurotoxin receptor site 3 (S3b-S4 linker region) slowing or 
preventing NaV fast inactivation (53-55). Although distinct NaSpTx families have been 
proposed, spider toxins have been shown to act promiscuously, being able to not only 
interact with various domain paddle motifs of the same NaV (26) but also different NaV 
isoforms, and even channel subtypes (NaV, KV, CaV).
1.6.2 Scorpion Toxins
Scorpion toxins (NaScTx) come in two major types; α-NaScTxs(56) and β-
NaScTxs (57), which are then further subdivided in their respective clades. NaScTxs 
are typically between 60 to 80 residues in length stabilized by 4 disulfide bonds. α-
NaScTxs and β-NaScTxs used to be classified by old world (α-NaScTxs) vs new world 
(β-NaScTxs), but since the line between them is being blurred (58), they are nowadays 
characterized by their neurotoxin binding site instead. α-NaScTxs bind to neurotoxin 
receptor site 3 and slow or inhibit NaV fast inactivation (59, 60). They are further 
subdivided into 3 classes (61): 1) classical α-NaScTxs, which target mammalian NaVs, 
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2) anti-insect α-NaScTxs, which, as the name implies, target only insect NaVs, and 3) α-
like α-NaScTxs, which are active on both mammalian and insect NaVs. β-NaScTxs 
target neurotoxin receptor site 4 and tend to push channel activation towards more 
depolarized potentials by a voltage-sensor trapping mechanism (62, 63). They are 
subdivided into 4 classes (61): 1) anti-mammalian β-NaScTxs, which target mammalian 
NaVs, 2) anti-mammalian/insect β-NaScTxs, which act on both mammalian and insect 
NaVs, 3) anti-insect excitatory β-NaScTxs, and 4) anti-insect depressant β-NaScTxs. All 
NaScTxs share a similar three dimensional βαββ fold held together by their 4 disulfide 
bonds. Since NaScTxs bind to there cognate receptors in a state dependent manner, 
they may hold the key to truly unraveling mechanism of action at an atomic level.
1.6.3 Sea Anemone Toxins
Sea anemone use neurotoxins for both predatory and defense mechanisms. 
There have been over 50 sea anemone toxins described in the literature that target 
NaVs and they mainly fall into 1 of 3 types (with a few exceptions that don't fall into any 
of these 3 types) based on their sequence homology (64). Type 1 & 2 sea anemone 
toxins are considered the long toxins, and are 46 to 51 residues in length with a 
conserved disulfide bridge motif of Cys1-Cys5, Cys2-Cys4, Cys3-Cys6. Type 3 are the 
short sea anemone toxins that are 27 to 32 residues in length with either 3 or 4 disulfide 
bonds. Sea anemone toxins target neurotoxin receptor site 3, slowing or preventing fast 
inactivation in NaVs as seen with anthopleurin A (ApA), anthopleurin B (ApB), and ATX-
II, all of which inhibit fast inactivation of NaV1.5 (65). These toxins have been shown to 
bind the channel in a voltage-dependent manner (66), similarly to NaScTx.
 13
1.6.4 Marine Snail Toxins
The super family Conoidea represents three families of predatory marine snails, 
the well studied Conidae (cone snails), and the lesser studied Terebridae (terebrids) and 
Turridae (turrids). As stated earlier, each species of cone snails is thought to produce 
upwards of 200 conotoxins. Considering that 1700 species have been described so far, 
this creates an immensely huge natural resource library (43, 44). The well studied cone 
snails have a diverse array of conotoxins with 9 pharmacological families described to 
date (α, χ, δ, ε, ɣ, ɩ, κ, μ, ω, ρ, σ, conantokin), and each of these families can be further 
subdivided based on their unique cysteine framework (44). Conotoxins range from 6 to 
84 residues in length. Out of the 9 pharmacological families described, 3 are active 
against NaVs. The μ-conotoxins are known NaV pore blockers, interacting with site 1 
(67). Although the site of interaction is still not known, ɩ-conotoxins activate NaVs without 
affecting fast inactivation (68, 69). Lastly δ-conotoxins interact with the voltage sensor 
of domain IV, neurotoxin receptor site 6 (70, 71). δ-conotoxins are known to prolong 
channel opening by slowing channel inactivation. Terebrids and Turrids, although less 
studied, hold similar promise of a diverse library of biologically active NaV neurotoxins 
(43) that may finally be unraveled thanks to the advent of next generation sequencing 
(72).
1.6.5 A Promise of Peptide Neurotoxins
One way in which toxins can aid in structural studies is that they are known to 
“lock” channels in certain conformations, be it activated, closed, or inactivated. Using 
toxins known to lock channels in each specific conformation and using techniques such 
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as X-ray crystallography, NMR, and even cryo-EM (if sufficiently high resolution can be 
obtained), one can theoretically map a mechanism of action for the VSDs and channels. 
Since peptide neurotoxins are highly specific and have great affinity for their cognate 
VGIC, there is high potential for their use as a drug or a model for drug development, 
fine tuning channel activity and thereby alleviating symptoms in channelopathies (73). In 
2004, the Food and Drug Administration (FDA) approved ziconotide (Prialt) as a drug to 
alleviate intense and chronic pain typically found in HIV and cancer patients (74). 
Ziconotide is a peptide neurotoxin derived from the cone snail, Conus magus, which 
alters CaVs of neuronal cells in the pain pathway (74, 75). If the toxin-VSD interaction 
can be elucidated, molecules imitating the pharmacology of these peptides can be 
developed, allowing for easier methods of administration, specificity, and longevity. 
These interactions can be brought to light by various NMR methods (76) as well as 
cross-linking and mutational studies. 
1.7 Probing Biology Through NMR Spectroscopy
NMR has proven to be a powerful tool in structurally and dynamically studying proteins 
since it was first used to determine the structure of proteinase inhibitor IIA from bull 
seminal plasma in 1985 (77). The simplest set of NMR experiments one can run for 3D 
structure determination of a protein consists of the 2-dimensional (2D) homonuclear 
1H-1H Correlation Spectroscopy (COSY), Total Correlation Spectroscopy (TOCSY), and 
Nuclear Overhauser Spectroscopy (NOESY) experiments. The 2D 1H-1H COSY and 
TOCSY experiments allow for the identification and establishment of amino acid spin 
systems, where magnetization is transferred through bonds via j-coupling. The 2D 1H-1H 
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NOESY experiments allow for the establishment of distance restraints as magnetization 
is transferred through space via dipolar couplings. Using the two types of experiments in 
conjunction allows sequential assignments to be made, and has been termed a COSY/
TOCSY-NOESY walk. These 2D 1H-1H homonuclear techniques are routine for structure 
determination of soluble proteins less than 55 residues in length - typical of peptide 
toxins (78, 79). For proteins larger than 55 residues the spectral overlap in 2D 
homonuclear 1H-NMR becomes too great to overcome, and isotopic labeling with 15N 
and 13C is needed. Isotopic labeling of proteins allows 2D and 3-dimensional (3D) 
heteronuclear experiments that reduce the spectral overlap. 3D triple resonance NMR 
experiments such as HNCOCA(CB) and HNCA(CB) have made sequential assignments 
routine for larger proteins. However, an important drawback of working with large 
proteins or systems (such as membrane proteins solubilized in membrane mimetics) is 
the slow isotropic tumbling of the system leading to increased line broadening with 
increased molecular weight. One way to circumvent this issue is through the use of 2D 
and 3D transverse relaxation-optimized spectroscopy (TROSY) based experiments, 
where the spectral sensitivity and resolution is improved as discussed by Fernández 
and Wider (80) and demonstrated for various membrane proteins in both micelles (28, 
81) and even larger bicelles (82, 83). NMR is not only useful for deriving structural 
information, but is also a powerful method for looking at binding interactions and 
dynamic states ranging on the time scales of picoseconds to seconds, and even longer. 
Experiments such as cross saturation can be used to determine direct binding 
interfaces of biomolecules, as was done to determine the residues involved in binding of 
the peptide toxin VSTx1 with the VSD of KVAP in n-decyl-ß-D-maltopyranoside (DM) 
 16
micelles (84). Binding can also be probed using changes in peak position in 15N-
heteronuclear single quantum coherence spectroscopy (HSQC), which will not only 
provide information on residues involved in binding but also residues involved in 
conformational changes. NMR spectroscopy can also give information about protein 
backbone flexibility (spin relaxation experiments), orientational information based on 
residual dipolar couplings (RDCs), and protein folding and unfolding (ZZ exchange 
experiments) - all reviewed in (85, 86). The ability of NMR to not only determine protein 
structure, but also probe protein dynamics makes NMR an invaluable tool for the life 
sciences.
1.8 Scope of Work
Our group is interested in the structural characterization of peptide neurotoxins, 
in establishing a method for the discovery of novel gating-modifier toxins, and in 
elucidating VGIC structure and the interactions of gating-modifier toxins with their 
cognate receptors. Specifically we are interested in the structure of peptide neurotoxins 
and the VSDs of NaV channels. Here we bacterially expressed a human VSD (NaV1.5 
VSD IV) in quantifiable amounts, with the ability to isotopically label the protein. By 
immobilizing VSDs on a resin we were able to probe venom extract to pull down novel 
toxins. We have also subjected synthesized and folded peptide neurotoxins and NaV 
paddle motifs to various solution-state 2D homonuclear NMR techniques such as 
TOCSY and NOESY, 2D and 3D heteronuclear HSQC (both 1H-15N and 1H-13C), HNCO, 
HNCA, and HNCACB in structural characterization. Using the 15N TROSY we were able 
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to probe the feasibility of making sequential backbone assignments of the isolated 
human cardiac Nav1.5 VSD IV. 
The determination of assignments using NMR spectroscopy on isolated VSDs or 
paddle motifs and their neurotoxin complexes can reveal the interacting residues of 
toxins and their cognate receptors at atomic resolution(76). Elucidation of these key 
interactions of the (VSD/paddle motif)-toxin complexes and the conformational changes 
induced by the toxins (correlating with altered physiological responses or voltage-
dependent states) may facilitate the development of novel compounds that target and 
affect voltage activation of VGICs. NMR is a great tool for determining protein-protein 
(or ligand-protein) interactions, especially within the realm of membrane proteins (76, 
84). NMR allows for the visualization of protein dynamics, as relaxation properties of the 
nuclei within the protein will change based on the dynamic environment of the nuclei. 
Whereas membrane proteins are highly flexible and hydrophobic, which greatly 
decreases their ability to be crystallized, solution-state NMR allows for the structural 
study of membrane proteins by overcoming these difficulties since experiments can be 
conducted in a more native state using phospholipid bicelles. With the structural 
information obtained by way of solution state protein NMR, the development of novel 
therapeutic compounds can ensue that would capitalize on key interactions to increase 
specificity and lessen side effects caused by nonspecific interactions. 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Chapter 2
NMR Structure Of Tv1, A Novel Bioactive Peptide 
Toxin from Terebrid Marine Snails
Mohammed Bhuiyan, Prachi Anand, Alexandre Grigoryan, Jianqin Zhuang, Mandë 
Holford, Sébastien F. Poget
Adapted from the 2012 publication: Anand, Prachi, et al. "Sample limited characterization of a novel disulfide-rich venom peptide 
toxin from terebrid marine snail Terebra variegata." PloS one 9.4 (2014): e94122.
2.1 Abstract
Peptide toxins display great specificity in both targeting and function, and are a 
viable resource for enriching the available arsenal of pharmaceutical compounds. For 
example Ziconotide (Prialt), a peptide toxin derived from cone snails (conotoxin), is the 
first FDA approved conotoxin drug used to treat chronic pain in cancer and HIV patients 
by targeting voltage-dependent Ca2+ channels. Cone snail toxins have long been 
identified as effective compounds for characterizing ion channels and receptors. 
However, the Terebridae, a less studied, related venomous snail family, are believed to 
be an untapped pharmacologically relevant source of toxins. Similar to cone snails, 
genomic and proteomic analyses of terebrid venom reveal a vibrant diversity of peptide 
toxins (teretoxins). Here, we present the first structural elucidation of a teretoxin, Tv1. 
Tv1 was chemically synthesized, oxidatively refolded, and structurally characterized by 
nuclear magnetic resonance (NMR) spectroscopy. Standard homonuclear NMR 
methods were used in the structure determination, and the final bundle of lowest energy 
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structures revealed an unusual pattern of disulfide bond connectivities potentially unique 
to teretoxins. The NMR structure of Tv1 will assist in understanding the toxin's 
pharmacological properties, and is being used to guide the search for functional 
receptors of Tv1.
2.2 Methods
2.2.1 NMR Solution Structure Derivation
Chemically synthesized and folded Tv1 (79) was obtained from our collaborators 
from the Holford group at Hunter College. Toxin samples for Nuclear Magnetic 
Resonance (NMR) studies were prepared by dissolving lyophilized oxidized peptide into 
either a 9:1 ratio of H2O:D2O or in 100% D2O at a concentration of 260 µM. Sample pH 
was adjusted to pH 6.0 and 50 µM trimethylsilyl propanoic acid (TMS) was added as a 
reference compound. Spectral acquisition was carried out at 5 ℃ on a Varian Inova 600 
MHz NMR spectrometer equipped with a cryogenically cooled HCN probe. 2D-TOCSY 
(Total Correlation Spectroscopy) spectra were acquired in 90% H2O (64 scans with 
1024x512 points) and D2O (48 scans with 1024x512 points) with spin-lock times of 60 
mS, whereas 2D-NOESY (Nuclear Overhauser Spectroscopy) spectra were acquired 
with mixing times of 200 mS in H2O with a matrix size of 1024x512 points in 64 scans 
and in D2O with a similar matrix size in 112 scans. A natural abundance 1H/13C HSQC 
(Heteronuclear Single Quantum Coherence) correlation spectrum was also acquired in 
1024 scans with a matrix size of 1024x80 points. Acquired spectra were processed with 
NMRPipe (87) and analyzed with CCPNmr Analysis (88). Proton assignments were 
made by comparison of TOCSY and NOESY spectra, and used to assign the 13C 
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chemical shifts through the HSQC spectrum (Table 1). Distance restraints for structural 
calculations were obtained from 2 NOESY spectra: one spectrum collected in 90% H2O 
with a mixing time of 200 mS and another spectrum collected in D2O with a mixing time 
of 400 mS. Manual assignment was performed for about 90% of all NOE cross-peaks. 
Dihedral angle restraints were derived from the assigned chemical shifts using the 
software TALOS+ (89). Structural calculations were carried out with ARIA2 (90)/ CNS 
(91). Initial structural calculations were conducted using only the manual NOE 
assignments (with distances automatically calibrated by the software based on peak 
volumes) and without any restraints for the disulfide bonds. An ARIA2 run consisting of 
8 iterations of simulated annealing followed by explicit water refinement of the 10 
lowest-energy structures was performed. Disulfide connectivities were determined 
based on this initial structural bundle and included in the final round of structural 
calculations as covalent bonds. Eight iterations were performed in ARIA with 20 
structures generated per iteration and the 7 lowest energy structures of each iteration 
forming the structural ensemble for the next iteration. For this run, NOE assignments 
were allowed to be automatically adjusted by the software during the calculation. For 
the last iteration, 100 structures were generated, and ten lowest-energy solutions were 
subjected to explicit solvent refinement. The quality of the final structural bundle was 
assessed by Procheck NMR (Table 2) (92).
 21
2.3 Results and Discussion
2.3.1 Structural Characterization of a Teretoxin by Solution-State NMR     
         Spectroscopy
Tv1 is a major component of the venom from the terebrid marine snail Terebra 
variegata (79). As described in the 2014 paper by Anand et al. (79), venom was 
extracted from T. variegata by our collaborators by dissection of the venom glands and 
extraction by light sonication into 30% acetonitrile (0.1% TFA), purified by RP-HPLC, 
and subjected to de-novo sequencing by ETD- (Electron-Transfer Dissociation) and 
CAD- (Collisional Activated Dissociation) MS/MS. Sequencing results yielded a 21 
residue peptide (TR(I/L)CCGCYWNGSKDVCSQSCC). Because of their identical 
masses, it could not be determined if the amino acid residue at position 3 is an 
isoleucine or a leucine. Our collaborators performed bioactivity assays on polychaete 
worms which indicated that the isoleucine variant had biological activity. In addition, the 
NMR spectra were very similar except for resonances corresponding to isoleucine or 
leucine (Figure 2.1). Therefore, all further structural studies were carried out on the 
isoleucine variant. We subjected Tv1 to 2D homonuclear TOCSY and NOESY 
experiments as well as 2D natural abundance 13C-HSQC. The TOCSY spectrum was 
used to establish amino acid spin systems, while sequential assignments were made 
using a TOCSY-NOESY walk, allowing us to assign the proton resonances in both 
spectra (Figure 2.2, Table 1). The natural abundance 13C-HSQC aided in assignment of 
the N-terminal threonine since its nitrogen proton correlations were not visible, most 
likely due to rapid exchange with the solvent. The HSQC was also used to derive bond 
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angle restraints using TALOS+ (89) based on carbon chemical shift assignments (Table 














Figure 2.1: TOCSY comparison of Isoleucine vs Leucine variants of Tv1. An overlay of the 
fingerprint region of TOCSY spectra of the Isoleucine variant of Tv1(black) and Leucine variant of Tv1 
(blue) shows no major difference between the spectra except for resonances correlated to isoleucine 
and leucine, indicating that the overall structure is not affected by this amino acid subsitution.
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Figure 2.2: TOCSY-NOESY walk using 2D-homonuclear proton NMR. An overlay of NOESY (black) 
and TOCSY (green) spectra is shown. A representative NOESY-TOCSY walk showing the longest 
stretch of sequential assignments obtained from 19Ser to 12Ser (7 sequential residues) is highlighted. 
Vertical arrows represent the sequential i to i-1 connectivities.  The asterisk represents 14Asp as its 
signal was not observed in H2O TOCSY but Hα to Hβ correlation were observable in the D2O TOCSY. 
Figure 2.2: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying strong, medium, and weak 
NOE cross peaks between flanking residues (Cys7-Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18) of and 
between Cys16 and Cys7.
Figure 2.2: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying strong, medium, and weak 
NOE cross peaks between flanking residues (Cys7-Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18) of and 
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(green) showing NOESY-TOCSY walk showing the longest stretch of sequential assignments obtained 
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Figure 2.2: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying strong, medium, and weak 
NOE cross peaks between flanking residues (Cys7-Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18) of and 
between Cys16 and Cys7.
Figure 2.2: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying strong, medium, and weak 
NOE cross peaks between flanking residues (Cys7-Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18) of and 







Figure 2.1: TOCSY-NOESY walk using 2D-homonuclear proton NMR. NOESY (black) and TOCSY 
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Table S2. Chemical shift assignments of Tv1 (in ppm) 
	 H	 Hα	 Hβ	 Hγ	 Cα	 Cβ	 Cγ	 	
Thr	1	 	 4.07	 3.63	 1.26	 70.18	 65.06	 21.4	 	




55.49	 31.6	 26.81	 Hδ	3.19,	Cδ	43.42	






Cys	4	 7.48	 4.87	 3.75	
2.75	
	 53.89	 39.66	 	 	
Cys	5	 8.91	 5.45	 4.30	
2.58	
	 55.11	 48.6	 	 	
Gly	6	 8.78	 4.10	
4.50	
	 	 44.99	 	 	 	
Cys	7	 8.55	 5.89	 3.04	
2.69	
	 55.23	 49.51	 	 	
Tyr	8	 8.82	 4.97	 3.04	 	 	 41.28	 	 Hδ,*	7.01,	Hε,*	6.74	
Trp	9	 8.93	 5.2	 3.33	
3.25	
	 54.38	 30.5	 	 Hδ1	7.22,	Hε1	10.26,	Hε3	7.69,	
Hζ2	7.27,	Hζ3	6.96,	Hη2	7.04	
Asn	10	 7.91	 5.21	 2.46	
2.89	
	 	 39.19	 	 	
Gly	11	 5.47	 4.51,
3.51	
	 	 45.1	 	 	 	
Ser	12	 7.87	 4.33	 3.62	 	 59.24	 61.77	 	 	




55.28	 34.88	 22.89	 Hδa	1.18,	Hεa	2.86,	Cε	41.57	
Asp	14	 8.56	 5.2	 2.55	
2.40	
	 	 41.67	 	 	





Cys	16	 9.02	 5.73	 2.97	 	 55.22	 47.32	 	 	
Ser	17	 8.89	 4.7	 3.95	
3.86	
	 56.98	 65.24	 	 	




55.18	 29.85	 33.79	 	
Ser	19	 8.52	 4.36	 4.14	
4.00	
	 61.52	 63.4	 	 	
Cys	20	 7.56	 4.52	 3.34	
2.86	
	 55.45	 39.66	 	 	
	
Table 2.1: Chemical shift assignments of Tv1 (in ppm)
and only manually assigned Nuclear Overhauser Effect (NOE) distance restraints. The 
proximity of the cysteine residues found in these structures corroborated the mass 
spectrometry derived disulfide pattern. Observed NOE connectivities between HN of 
Cys16 and the Hα of Cys7 and connectivities to protons in the two flanking residues, 
Gly6 and Tyr8, provided further direct evidence of the disulfide bond between residues 
Cys7 and Cys16 (Figure 2.3). The final round of structure calculations included the 
TALOS+ derived bond angle restraints, NOE distance restraints, and covalent disulfide 
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Figure 2.3: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying NOE cross peaks between 
residues Cys7 and Cys16 and the flanking residues of their respective disulfide-bonding partner (Cys7-
Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18).
Figure 2.2: NOE connectivities confirming disulfide bond Cys7-Cys16. Overlay of the HN-Hα 
fingerprint region of the NOESY(black) and TOCSY(blue) spectra displaying strong, medium, and weak 
NOE cross peaks between flanking residues (Cys7-Ser17, Tyr8-Cys16, Gly6-Cys16, Gly6-Gln18) of and 








Figure 2.4: Structure calculation ensemble of Tv1. The ten lowest energy structures of Tv1 are 
shown, including only backbone atoms (top) and all atoms (bottom). These structure bundles illustrate 
the low RMSD values of 0.42 Å and 0.74 Å for backbone and all heavy atoms, respectively.
bonds (Cys3-Cys20, Cys4-Cys21, Cys7-Cys16). The 10 lowest energy structures 
showed an RMSD of 0.42 Å for backbone atoms, and 0.74 Å for all heavy atoms (Figure 
2.4 and Table 2). To determine wether Tv1 shared structural homology with other 
peptides we submitted a query using the software packages PDBeFOLD (93) and VAST 
(94), which yielded no hits. Tv1’s most prominent and well defined feature is its β-
hairpin formed between residues 5-10 and 13-18 clamped by the disulfide bridge 
formed between cysteines 7 and 16 (Figure 2.5). The fact that structural homology 
queries yielded no results indicates that Tv1 may represent a new fold not yet seen in 
small peptide toxins, although it does share a cysteine scaffold similar to M Superfamily 
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Table S3. Structural statistics for the final 10 models of Tv1 
Quantity	 	 	 	 	 	 	 	 Value	
Total	unambiguous	distance	restraints	 	 	 	 780	
	 Intra	residual		 	 	 	 	 	 556	
	 Sequential	(|	i	–	j	|	=	1)	 	 	 	 	 73	
	 Medium	(2	≤	|	i	–	j	|	≤	4)	 	 	 	 	 39	
	 Long	range	 	 	 	 	 	 	 112	
NOE	violations	in	all	models	
>	0.5	Å	 	 	 	 	 	 	 0	
>	0.3	Å	 	 	 	 	 	 	 9	
>	0.1	Å	 	 	 	 	 	 	 211	
RMSD	from	the	average	atomic	coordinates	(Å)	
	 Backbone	
	 	 Most	ordered	region	(residues	4-18)	 	 0.31	±	0.10	
	 	 All	residues	 	 	 	 	 	 0.42	±	0.21	
	 All	Atoms	
	 	 Most	ordered	region	(residues	4-18)	 	 0.59	±	0.29	
	 	 All	residues	 	 	 	 	 	 0.74	±	0.43	
Deviations	from	idealized	covalent	geometry	
	 Bond	(Å)	 	 	 	 	 	 	 0.0055	±	0.0003	
	 Angles	(°)	 	 	 	 	 	 	 0.72	±	0.045	
	 Improper	dihedrals	(°)	 	 	 	 	 1.94	±	0.14	
Ramachandran	analysis	(%)	
	 Residues	in	most	favored	regions	 	 	 	 61.2	
	 Residues	in	additionally	allowed	regions	 	 	 32.9	
	 Residues	in	generously	allowed	regions	 	 	 5.9	
	 Residues	in	disallowed	Regions	 	 	 	 0.0	
	
Table 2.2: Structural statistics for the final 10 models of Tv1
conotoxins. The structure of Tv1 is also dominated by tyrosine 8, which anchors a small 
hydrophobic core through hydrophobic interactions, namely with isoleucine 3 and valine 
15 (Figure 2.5). Observed differences in fold and disulfide pattern are not surprising due 
to the lack of sequence homology between M Superfamily conotoxins, even though they 
share a similar cysteine scaffolding. M Superfamily conotoxins do not display β-hairpin 
folds, leading us to believe that Tv1 is the prototype of a new and unique group of 
peptide toxins. 
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Figure 2.5: Structure of Tv1. Cartoon representation and a stick model of the lowest-energy structure 
of Tv1 shows the β-sheet character of the peptide and reveals the important role of the Tyr 8 side chain 
in the formation of a small hydrophobic core.
2.4 Conclusions
Here we present the first structural characterization of a teretoxin described in 
the literature. Our collaborators were able to identify the peptide sequence of Tv1 using 
4 ng of venom sample from T. variegata. There are over 400 species of terebrids in 
nature, and each is believed to express anywhere from 50 to 200 different peptides 
within its venom. Using the integrated approach of mass spectrometry to chemical 
peptide synthesis to NMR spectroscopy, as was applied to Tv1, it would be possible to 
study the structural features of many peptides found in minute quantities in nature, 
tapping into this vast pool of teretoxins. The novel structural features of Tv1 suggest that 
teretoxins may act by different mechanisms of action and have different cognate 
receptors compared to previously described disulfide peptide toxins. If Tv1’s biological 
target can be elucidated, this may open the door for sophisticated drug design 
experiments. Although the cognate receptor of Tv1 remains elusive, we can formulate a 
hypothesis of its mechanism of action based on the structural properties of Tv1. Based 
on surface potential calculations, Tv1 has a large positive surface potential with a 
protruding Arginine (Figure 2.6). In the literature, pore-blocking toxins have been 
described to have a lysine residue protrude into the pore and interact with residues 
lining the selectivity filter, occluding the passage of ions (95). If dimensions of the 




Figure 2.6: Electrostatic surface Potential of Tv1. Electrostatic surface potential of Tv1 showing a 
highly dense population of positive charges located on one face of the molecule. Electrostatic surface 
potential was generated using the APBS plugin for VMD, using a PQR file generated by the server 
PDB2PQR.
Chapter 3
Expression, Purification, and Preliminary 
Characterization of a Human Cardiac Sodium Channel 
Voltage-Sensor Domain
Mohammed H. Bhuiyan, Sebastian F. Poget
3.1 Abstract
Voltage-sensor domains (VSDs) of voltage-gated ion channels sense changes in 
the membrane potential and as a result alter the conduction state of the channel. The 
human voltage-gated sodium channel NaV1.5 is primarily expressed in cardiac muscle 
and is responsible for the rising phase of the cardiac action potential. Mutations within 
NaV1.5 can lead to fatal cardiac arrhythmias. Such mutations have been found 
throughout the gene, including missense mutations within the VSD of repeat IV that 
have been shown to lead to Brugada Syndrome and LQT3. The VSDs also play an 
important role as the binding sites for gating modifier peptide toxins from tarantula 
spider venoms. Such toxins could serve as good lead compounds for drug development 
due to their high specificity and subtler mode of action compared to pore blockers. 
Therefore, it would be important to know the structures of the human sodium channel 
VSDs. While no structures of whole eukaryotic sodium channel proteins exist, isolated 
VSDs of other ion channels have been shown to fold into their native conformation in 
the absence of the pore forming domain. Therefore, we are pursuing the expression and 
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purification of the isolated VSDs of human sodium channels in order to investigate the 
structural changes within the VSD caused by pathogenic mutations and by the binding 
of gating-modifier toxins. Here, we present the expression in isotopically labeled form 
and purification of the human NaV1.5 VSD of repeat IV in a bacterial expression system 
and preliminary characterization of the truncated protein. NaV1.5 VSD IV is expressed in 
Escherichia coli (E. coli) in minimal media, and extracted from membranes by 
solubilization into n-dodecylphosphocholine (n-DPC) micelles. Purified NaV1.5 VSD IV 
was characterized by mass spectrometry and gel filtration chromatography and used for 
preliminary Nuclear Magnetic Resonance (NMR) structural studies.
3.2 Methods
3.2.1 Cloning of NaV1.5 VSD IV
A synthetic gene coding residues 1512 to 1660 of NaV1.5 was purchased from 
GeneWizInc. and named NaV1.5VSDIV (see appendix A1). NaV1.5VSDIV was amplified 
by PCR using the primers (Fwd: 5’-CGCGCCATGGGCCGTCCGCTGAACAAGTAC-3’ and Rev: 5’-
GAGCTCGAGCGACCCACGCGGTACTAAGATGTTGAACAGGGCCGG-3’) at final concentration of 0.2 μM, 200 μM 
dNTPs, 1X standard Taq Reaction Buffer (NEB), 1.25 units of Taq DNA polymerase 
(NEB) and less than 1 μg of NaV1.5VSDIV in a 50 μL reaction. The thermocycles were 
as follows 95 ℃ for 30 seconds, then 30 repetitions of 95 ℃ for 30 seconds, 51.1 ℃ for 
30 seconds, 68 ℃ for 30 seconds, and a final elongation step of  68 ℃ for 5 minutes. 
The amplified gene was gel purified using Wizard® SV Gel and PCR Clean-Up System 
(Promega) and introduced into pET28b+ expression vector (Novagen) between 
restriction sites NcoI and XhoI (pNaV1.5VSDIVsynth coding for NaV1.5 VSD IV-6H). The 
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forward primer coding for the restriction site NcoI introduced two residues (Met and Gly) 
to the recombinant protein. pNaV1.5VSDIVsynth was subjected to standard PCR 
mutagenesis, following the manufacturer’s protocol for QuikChange II XL site- directed 
mutagenesis kit (Agilent) to incorporate three codons coding for histidine, extending the 
existing histidine tag from six to nine residues (pNaV1.5VSDIVsynth-9H) using the 
p r i m e r s ( F w d : 5 ’ - T G G G T C G C T C G A G C AT C AT C AT C A C C A C C A C C A C C - 3 ’ a n d R e v : 5 ’ -
GGTGGTGGTGGTGATGATGATGCTCGAGCGACCCA-3’). 
3.2.2 Expression Trials of NaV1.5 VSD IV-6H
Expression trials of NaV1.5 VSD IV-6H (encoded in pNaV1.5VSDIVsynth) were 
carried out in six E. coli expression cell lines (BL21 (DE3)-AI, BL21 (DE3), BL21 (DE3)-
pLysS, BL21 (DE3)-pLysS-star, Rosetta (DE3) 2, C43 (DE3)) in 50 mL of rich media in 
250 mL autoclaved erlenmeyer flasks. Each expression cell line was tested in various 
expression conditions, with variable temperature, Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) concentration and time. All cell lines were tested with an induction temperature 
of 37 ℃, OD600 of ~1.0, induced for 3 H with either 0.5 mM or 1 mM IPTG; with an 
induction temperature of 22 ℃ with an inducer concentration of either 0.5 mM or 1 mM 
IPTG upon OD600 reaching ~1.0, with 5 different induction periods (0 H, 2 H, 4 H, 6 H, 
and 22 H). Samples of 100 μL were collected, centrifuged at 1180 x g for 5 minutes, and 
the supernatant discarded. Western blot analysis (see appendix A2 and A3) showed 
Rosetta (DE3) 2 to be the most promising expression strain at 22 ℃. Rosetta (DE3) 2 
was then selected for further expression optimization in M63 minimal media (see 
appendix A4) at an induction optical density of ~1.0, with various pH’s (6, 7, 8), 
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temperatures (37 ℃, 22 ℃, 12 ℃) two inducer concentrations (0.5 mM and 1 mM 
IPTG) and variable induction times.
3.2.3 Expression of NaV1.5 VSD IV-9H
Expression of the recombinant protein NaV1.5 VSD IV-9H (NaV1.5 VSD IV 
containing a nine residue His-tag separated by a thrombin cleavage site) was carried 
out by transformation of the plasmid into the expression cell line Rosetta 2 (DE3) 
(Novagen). A liquid culture of the transformed cells was grown overnight at 37 °C in LB 
supplemented with 50 µg/mL of kanamycin and 34 µg/mL chloramphenicol. On the 
subsequent morning fresh M63 minimal media (pH 6.0) containing 3 g of D-glucose, 50 
µg/mL kanamycin, 34 µg/mL chloramphenicol, and 1 g of either 14N-NH4Cl or 15N-NH4Cl 
was inoculated with the overnight culture in a ratio of 1 mL to 50 mL to obtain a starting 
OD600 of 0.05-0.1. Inoculated cultures in M63 were grown at 37 °C with shaking at 225 
rpm until the OD600 was ~0.7, at which point the temperature was reduced to 12 °C and 
shaking increased to 250 rpm until the OD600 reached ~1.0. Protein expression was 
induced by the addition of IPTG at final concentration of 1 mM and the cells grown for 
an additional 42.5 H.
3.2.4 Isolation of E. coli Membranes
Harvested cells were treated with 5 ml of lysis mixture (50mM sodium phosphate 
(NaPi) pH 7.3, 300mM sodium chloride (NaCl), 0.2mg/mL lysozyme, 0.02mg/mL DNase 
I, 1mM magnesium chloride (MgCl2), 1mM phenylmethylsulfonyl fluoride (PMSF)) per 
gram of wet cell pellet. Resuspended cells were sonicated and centrifuged at 7649.2 x g 
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and 4 °C (low speed spin) for 15 minutes to remove non-lysed cells and large cellular 
debris. The supernatant was subjected to a second low speed spin. The second 
supernatant was then subjected to ultracentrifugation (285000 x g at 4 °C for 90 
minutes) to obtain the E. coli membranes. Membrane pellets were stored at -20 °C 
when not used.
3.2.5 Detergent Screen
E. coli membranes were resuspended by sonication in resuspension buffer 
(50mM NaPi, 300mM NaCl, 1mM PMSF), and aliquoted. Resuspended membranes 
were then treated with various detergents (Dodecyl Maltoside (DDM), Decyl Maltoside 
(DM), Octyl β-D-galactopyranoside (OβG), Fos-Choline 14 (FC14), Fos-Choline 10 
(FC10), n-Dodecylphosphocholine (n-DPC)) at 5% w/v. Detergent extraction was carried 
out at room temperature for 2 H, and the extracts were then subjected to centrifugation 
at 12557 x g at 4 °C for 20 minutes.
3.2.6 Purification of NaV1.5 VSD IV-9H
Membrane pellets were resuspended by sonication in resuspension buffer to give 
a concentration of 100 mg of wet membrane per 1 mL of resuspension buffer. 
Resuspended membranes were treated with 2.5% n-DPC for detergent extraction. 
Detergent extraction occurred over 2 H at room temperature with gentle rocking. The 
extraction solution was then centrifuged at 34541 x g (Sorvall ss-34 rotor) at 4 °C. The 
supernatant was then subjected to immobilized metal affinity chromatography (IMAC). 
The sample on ice is loaded with a peristaltic pump on to a pre-equilibrated 1 mL GE 
TalonTrap (GE Healthcare Life Sciences) (equilibrated with 50mM NaPi (pH 7.3), 
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300mM NaCl, 5 mM n-DPC (equilibration buffer)) at a flow rate of 1 mL/minute on ice by 
a peristaltic pump (Econo Pump by Bio-Rad). Upon the completion of column loading 
the column is attached to a GE AKTA FPLC system (GE Healthcare Life Sciences) and 
subjected to the following gradient: 10% elution buffer (equilibration buffer containing 
300 mM Imidazole) for 10 minutes, 10%-100% elution buffer over 10 minutes, and 
100% elution buffer for 10 minutes; a total run time of 30 minutes. The purification was 
fractionated into 1 mL aliquots for the total 30 minute run. 
3.2.7 Characterization of NaV1.5 VSD IV-9H
Collected fractions from IMAC purification were analyzed by SDS-PAGE and 
those containing the desired protein were pooled, concentrated to ~0.5 mL, and the 
imidazole concentration reduced using several concentration-dilution cycles using a 
Millipore centrifugal 3 kDa or 30 kDa molecular weight cut off (MWCO) filter with 
equilibration buffer as above used for the dilution. Concentrated samples were mixed in 
a 1:10 ratio with matrix solution (saturated α-Cyano-4-hydroxycinnamic acid (4-HCCA) 
in 3:1:2 formic acid: water: isopropanol), spotted onto a steel target (Bruker) pre-coated 
with a thin layer of 4-HCCA (96), and subjected to matrix-assisted laser desorption/
ionization - time of flight (MALDI-TOF) mass spectrometry carried out on a Bruker 
Microflex MADLI-TOF mass spectrometer. Samples were also subjected to size 
exclusion chromatography on a manually packed Tricorn 10/300 column with Superdex 
200 resin (both from GE Health Life Sciences) on a GE AKTA FPLC system, running an 
isocratic elution of 50 mM NaPi (pH 7.3), 300 mM NaCl, and 5 mM DPC.
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3.2.8 Toxin Pull down from Crude Gramostola rosea Venom by NaV1.5 VSD IV-9H
Lyophilized venom obtained from Grammostola rosea (G. rosea) by electro-
stimulation was dissolved in 500 µL of equilibration buffer, treated with pre-equilibrated 
Talon Co2+ resin, incubated for 15 minutes and centrifuged at 500 x g. The supernatant 
was collected, and the resin washed twice with 750 µL of equilibration buffer. All 
supernatants were collected and pooled and will be referred to as pre-depleted venom. 
They were split into two 1 mL aliquots and incubated as above with either pre-
equilibrated bare Talon Co+2 resin or NaV1.5-DIV-9His-bound Talon Co+2 resin. The 
resins in this case were washed with equilibration buffer containing 20 mM imidazole, 
and the washes collected. The resins were then treated with equilibration buffer 
containing 500 mM imidazole and collected. All fractions were then analyzed by MALDI-
TOF mass spectrometry.
3.2.9 Reconstitution of NaV1.5 VSD IV-9H into bicelles
The long chain lipid DMPC (Avanti Polar Lipids) dissolved in chloroform was 
dried under argon, washed with pentane and dried down with argon 3 times, and placed 
under vacuum for 30 minutes to remove residual solvent. Dried DMPC is then 
resuspended in 50 mM NaPi (pH 7.3) and 0.025% NaN3 by high power sonication for 30 
minutes. NaV1.5 VSD IV-9H dissolved in n-DPC micelles is added to the hydrated 
DMPC in a 1:75 protein to long chain lipid molar ratio, and dialyzed extensively against 
50 mM NaPi (pH 7.3), 0.05% NaN3. Proteoliposomes are then harvested by 
ultracentrifugation (285000 x g at 20°C) and resuspended with DHPC:n-DPC in 300 µL 
of 20 mM sodium acetate (NaOAc) (pH ~5), 20 mM NaCl, 10mM dithiothreitol (DTT), 
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and 0.05% NaN3 to obtain a final molar ratio of 1:2:1 DMPC:DHPC:n-DPC ratio based 
on the initial amount of DMPC in the vesicles. Final ratio of DMPC:DHPC:n-DPC was 
analyzed by 1D 31P NMR on a Varian Inova 300MHz spectrometer at The College of 
Staten Island.
3.2.10 Preliminary NMR studies of NaV1.5 VSD IV-9H
15N-NaV1.5 VSD IV-9H was prepared in n-DPC micelles to a concentration of 270 
µM in 10 mM NaPi (pH 7.3), 50 mM NaCl, 10% D2O, and 50 µM trimethylsilyl propanoic 
acid. This NMR sample was used to collect a 15N-HSQC at 40℃ (160 scans, 2048x128 
points). 15N-TROSY was collected on ~300 µM 15N-NaV1.5-DIV-9His in 300 µL of 20 mM 
NaOAc (pH ~5), 20 mM NaCl, 10 mM DTT, 0.05% NaN3 in a 1:2:1 DMPC:DHPC:n-DPC 
(10% total lipid concentration), 10% D2O, 10 mM DTT, and 100 μM 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) at 25 ℃ and 42 ℃. All data acquisitions were 
collected on a Varian Inova 600 MHz NMR spectrometer equipped with a HCN cryo-
probe. All acquired data were processed with NMRpipe (87) and analyzed with CCPNmr 
Analysis (88). 
3.3 Results and Discussion
3.3.1 Expression of an isolated NaV VSD
Expression trials of NaV1.5 VSD IV-6H in various E. coli expression strains 
(strains listed above) showed no expression at 37 °C by western blot analysis. Since 
other groups have had success with expression of mammalian proteins at lower 
temperature (81, 97) we decided to carry out further expression trails at 22 °C and 12 
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Figure 3.1: Expression trials of NaV1.5 VSD IV-6H in six different E. coli expression cell lines. 
Western blot analysis of the level of VSD expression was conducted using an anti-His antibody. All 
samples were induced at OD600 of ~1.0, using two different inducer concentrations of IPTG (0.5mM or 
1mM) and left to express at 22℃ for 22 H. Samples were taken before and 3,4,6 and 22 H after 
induction. Greatest expression was observed in E. coli expression cell line Rosetta (DE3) 2 after 22 H.
3h
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Figure 3.1: Expression trials of NaV1.5VSDIV-6H in six different E.coli expression cell lines. Expression conditions being an induction 
OD600 of ~1.0, two different inducer concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22hrs. Greatest expression was observed in e.coli 
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°C. All strains showed expression at 22 °C, with Rosetta (DE3) 2 showing the most 
expression (Figure 3.1). Therefore Rosetta 2 (DE3) was selected for further optimization 
in minimal media. Expression trials in M63 minimal media were carried out at 22 °C with 
varying pH (6, 7, and 8) and inducer concentration (0.5 mM and 1 mM IPTG) for 22 H. 
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Figure 3.2: Expression trials in M63 minimal media of NaV1.5 VSD IV-6H in E. coli expression cell 
line Rosetta (DE3) 2. Western blot analysis using an anti-His antibody of expression trials in M63 
minimal media. Expression was induced at OD600 of ~1.0 with two different inducer concentrations of 
IPTG (0.5 mM or 1 mM), and allowed to proceed at 22 ℃ for 22 H at pH 6, 7 and 8. Greatest 
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line Rosetta (DE3) 2. Expression conditions being an induction OD600 of ~1.0, two different inducer 
concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22 hours at pH 6, 7 and 8. Greatest expression 





































































































































































































































































































































































































































































Figure 3.2: Expression trials in M63 minimal media of NaV1.5VSDIV-6H in E.coli expression cell 
line Rosetta (DE3) 2. Expression conditions being an induction OD600 of ~1.0, two different inducer 
concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22 hours at pH 6, 7 and 8. Greatest expression 
was observed in M63 minimal media pH’d at 6 over 22 hours.
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Figure 3.3: Expression trials of NaV1.5VSDIV-6H in Rosetta (DE3) 2 in M63 minimal media.
Expression at 22℃ vs 37℃ vs 12℃. Expression conditions being an induction OD600 of ~1.0, two
different inducer concentrations of IPTG (0.5mM or 1mM) at 22℃ over 22hrs or 37℃ at variable time
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Figure 3.3: Expression trials of NaV1.5 VSD IV-6H in Rosetta (DE3) 2 in M63 minimal media. 
Western blot analysis of the expression trials at 22 ℃ vs 37 ℃ vs 12 ℃. Expression was induced at 
OD600 of ~1.0 with two different inducer concentrations of IPTG (0.5mM or 1mM) and allowed to 
proceed at 22℃ for 22 H; or at 37 ℃ or 12 ℃ for variable lengths of time. Greatest expression was 
observed at 22℃ over 22 H and 12℃ over 22 H-42.5 H.
Expression carried out at pH 7 and 8 yielded little to no protein expression when 
compared to expression carried out at pH 6 (with different inducer concentrations tested 
having almost no effect on the level of protein expression) as determined by western 
blot analysis (Figure 3.2). We finally tested expression at 12 °C, similarly to the 
expression of the vasopressin V2 receptor (97), in M63 minimal media at pH 6 for 42.5 
H with samples collected a various points throughout the growth - 42.5 H being the 
optimal time for maximal protein expression (Figure 3.3). The increased protein 
production at lower temperatures may be indicative of better protein folding, allowing the 
expressed human cardiac VSD to reach the E. coli membranes as opposed to miss-
folding and being destined for degradation. The ability to express NaV1.5 VSD IV-9H in 
an E. coli expression system in minimal media allows for isotopic labeling as was done 
by Sander’s group with KCNQ1 VSD (81) and McKinnon’s group with KvAP VSD (28), 
paving the way for sophisticated structural studies.
3.3.2 Purification and Characterization of the Human Cardiac VSD IV
Harvested cells containing NaV1.5 VSD IV-9H were lysed, the lysate was cleared 
of large debris by slow centrifugation and E. coli membranes harvested by 
ultracentrifugation. Membranes were resuspended and the extraction efficiency of 
various non-ionic detergents (DM, DDM, OβG), and the zwitterionic detergents (FC10, 
FC14, n-DPC) (Figure 3.4) to obtain NaV1.5 VSD IV-9H was tested. NaV1.5 VSD IV-9H 
was extracted very poorly in the non-ionic detergents with almost all of the protein found 
in the insoluble pellet. In contrast, it was extracted very well in the zwitterionic alkyl-
phosphocholine detergents FC10 and n-DPC (Figure 3.4). For purification purposes, 
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membranes were solubilized and treated with 2.5% DPC for the extraction of NaV1.5 
VSD IV-9H. Extracted NaV1.5 VSD IV-9H was then purified by IMAC using GE 
TalonTrap Co+2 columns. The resin was treated with a 30 mM imidazole wash to 
remove non-specific protein binders, and then treated with a gradient of 30 mM to 300 
mM imidazole. NaV1.5 VSD IV-9H eluted from the resin at a concentration of 150 mM 
imidazole and showed an apparent mass of ~19 kDa by SDS-PAGE (Figure 3.5).
Pooled fractions were then concentrated to ~500 μL by centrifugal filtration and desalted 
by gel filtration chromatography. The size exclusion chromatogram showed an elution 
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Figure 3.4: Detergent screen and extraction trial of heterologously expressed NaV1.5 VSD IV-9H 
from Rosetta (DE3) 2 membranes. Six membrane mimetics (n-Dodecyl-β-D-maltopyranoside (DDM), 
n-Decyl-β-D-maltopyranoside (DM), Octyl β-D-galactopyranoside (OβG), Fos-Choline 14 (FC14), Fos-
Choline 10 (FC10), n-Dodecylphosphocholine (n-DPC)) were screened for their ability to extract the 
VSD from the cell membrane, as detected by western blot analysis of the insoluble and soluble fractions 
using an anti-His antibody. n-DPC showed the highest ratio of solubilized to insoluble VSD and was 




























































































Figure 3.4: Detergent screen and extraction trial of heterologously expressed NaV1.5VSDIV-9H 
from Rosetta (DE3) 2 membranes. Six membrane membrane mimetics (Dodecyl Maltoside (DDM), 
Decyl Maltoside (DM), Octyl β-D-galactopyranoside (OβG), Fos-Choline 14 (FC14), Fos-Choline 10 
(FC10), n-Dodecylphosphochile (n-DPC)) were screened with n-DPC showing the most promise in 
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Figure 5: Purification and SDS-PAGE analysis of NaV1.5-DIV-NonaHis. NaV1.5-DIV-NonaHis was pulled out 
from e.coli membranes by IMAC. NaV1.5-DIV-NonaHis was loaded onto a GE TalonTrap Co+2 column and 
attached to a GE AKTA FPLC system  running a gradient of 30mM imidazole for 10 minutes increasing from 
30mM to 300mM imidazole over 10 minutes and 300mM for the final 10 minutes. (A) The FPLC 
chromatogram indicates NaV1.5-DIV-NonaHis elutes between 90-150mM imidazole. (B) SDS-PAGE analysis 
indicates NaV1.5-DIV-NonaHis is the major species within the eluted peak (fractions A15-B12). Black box 
indicates position of NaV1.5-DIV-NonaHis on gel.
(A)
(B)
Figure 3.5: Purification and SDS-PAGE analysis of NaV1.5 VSD IV-9H. NaV1.5 VSD IV-9H was 
purified from extracted E. coli membranes by IMAC. NaV1.5 VSD IV-9H was loaded onto a GE 
TalonTrap C +2 colum  and attached t  a GE AKTA FPLC system running a gradie t of 30mM 
imidazole for 10 minutes increasing from 30mM to 300mM imidazole over 10 minutes and 300mM for 
the final 10 minutes. (A) The FPLC chromatogram indicates NaV1.5 VSD IV-9H elutes between 
90-150mM imidazole. (B) SDS-PAGE analysis indicates NaV1.5 VSD IV-9H is the major species within 
the eluted peak (fractions A15-B12). Black box indicates position of NaV1.5 VSD IV-9H on SDS-PAGE 
gel.
profile consistent with a particle mass of approximately 60 kDa (Figure 3.6). IMAC and 
gel filtration data suggests that the over expressed recombinant protein NaV1.5 VSD 
IV-9H is expressed as an embedded integral membrane protein within the E. coli 
membrane that can be extracted with detergent and travels as a molecular complex 
much larger than the unsolvated VSD when analyzed by gel filtration chromatography. 
Furthermore, the fact that the protein is embedded in the E. coli membrane may be 
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Figure 8: Gel filtration chromatography purification of 15N-NaV1.5-DIV-NonaHis. NaV1.5-DIV-NonaHis was concentrated into ~500uL and loaded onto GE AKTA FPLC system equipped with 
Superdex 200 10/300 GL column. The shoulder of the major peak (fractions A8-A10) containing oligomeric states of NaV1.5-DIV-NonaHis and fractions A11-13 containing monomeric NaV1.5-
DIV-NonaHis.Figure 3.6: Gel filtration chromatography purification of 15N-NaV1.5 VSD IV-9H. NaV1.5 VSD IV-9H 
was concentrated into ~500uL and loaded onto GE AKTA FPLC system equipped with a Superdex 200 
10/300 GL column. Based on NMR analysis, it was found that the shoulder of the major peak (fractions 
A8-A10) contains oligomeric states of NaV1.5 VSD IV-9H and fractions A11-13 contain monomeric 
NaV1.5 VSD IV-9H. 
indicative of a properly folded protein, which eliminates the need for the non-trivial job of 
refolding. MALDI-TOF mass spectrometry was used to confirm the presence of NaV1.5 
VSD IV-9H in the purified sample and to determine isotope incorporation. The 
calculated molecular weight of NaV1.5 VSD IV-9H is 19420.2 Da and we observed a 
mass of 19421.8 Da (Figure 3.7A). Additionally, we confirmed that we were able to 
isotopically label NaV1.5 VSD IV-9H to a 95.8% 15N isotopic incorporation (expected 
mass: 19657.2 Da; observed: 19646.8 Da) (Figure 3.7B). Although the SDS-PAGE of 
purified NaV1.5 VSD IV-9H shows additional bands at higher apparent molecular weight 
(30 and 45 kDa), no such species are observable in MALDI-TOF (Figure 3.7A). This 
may indicate that those species may be aggregates of NaV1.5 VSD IV-9H. Following the 
above protocol, we are able to routinely obtain 1mg of pure, unlabeled VSD starting 
from 1 L of growth medium. The ability to produce isotopically labeled VSD will open the 
door to future atomic resolution structural and dynamic studies, namely by NMR 
spectroscopy (28, 81). By utilizing isotopically labeled VSDs and NMR spectroscopy, 
one can potentially characterize the residues involved in toxin binding, and even further 
by utilizing various toxins (β-scorpion and spider toxins) one can derive a mechanism of 
action for NaV VSDs; as these toxins lock their voltage-sensor in state dependent 
manners (45).
3.3.3 Pull down of Novel Site 3 Gating Modifier Toxins
Gating modifier toxins are a known component of tarantula venom. Tarantula 
venoms are known to contain both site 3 and site 4 toxins (98, 99, 100, 101). To aid in 























































































































































































































































































































































































































































































































































































































































































































































































treated the resin with pre-depleted venom obtained from the tarantula Grammostola 
rosea. Upon elution of NaV1.5 VSD IV-9H from the resin after treatment with pre-
depleted venom, two species were pulled down from the venom showing masses of 
3963.4 Da and 4004.9 Da. Additionally, we also observed an enrichment of the toxin 
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Figure 7: MALDI-TOF analysis of toxin pulldown from Grammostola rosea by NaV1.5-DIV-NonaHis. (A) Pre-depleted venom. (B) 500mM imidazole elution of pre-depleted 
venom incubated with pre-equilibrated bare GE Talon Co+2 resin showing two species showing masses of 4067.1 Da and 4102.2 Da (C) 500mM imidazole elution of pre-
depleted venom incubated with pre-equilibrated GE Talon Co+2 resin loaded with NaV1.5-DIV-NonaHis showing two species are pulled down (4069.0 Da and 4103.8 Da) 




Figure 3.8: MALDI-TOF analysis of toxin pull down from Grammostola rosea by NaV1.5 VSD 
IV-9H. (A) Pre-depleted venom. (B) 500mM imidazole elution of pre-depleted venom incubated with pre-
equilibrated bare GE Talon Co+2 resin showing two species with masses of 4067.1 Da and 4102.2 Da 
(C) 500mM imidazole elution of pre-depleted venom incubated with pre-equilibrated GE Talon Co+2 
resin loaded with NaV1.5 VSD IV-9H showing two species are pulled down (4069.0 Da and 4103.8 Da) 
(D) Overlay spectra of 500mM imidazole fraction of bare resin (red) vs. NaV1.5-DIV-NonaHis bound 
resin (black), indicating an enrichment of the smaller species by the presence of NaV1.5-DIV-NonaHis.
in the control sample (Figure 3.8). Upon searching the data base ArachnoServer (102) 
for toxins within ± 10 Da from G. rosea, only two hits were returned (VSTX1:3997.7 Da 
and ω-therapohotxin-Gr2a:4073.8 Da), but no exact matches to the observed masses 
were found. Employing this method of site 3 gating modifier toxin discovery can open 
avenues to toxin characterization and drug development in the treatment of 
channelopathies that affect the human cardiac VSD IV, such as LQT3 (103), Brugada 
syndrome (104), and progressive familial heart block (105).
3.3.4 NaV1.5 VSD IV-9H Show Enhanced Spectral Quality In Bicelles
15N-isotopically labeled NaV1.5 VSD IV-9H was subjected to 2D-heteronuclear 
15N-TROSY experiments in either n-DPC micelles or 1:2:1 DMPC: DHPC: n-DPC 
bicelles. Upon analysis of the 15N-NaV1.5 VSD IV-9H in n-DPC micelles we saw little to 
no signal in the 15N-TROSY experiments, indicating that the protein either takes multiple 
conformations that are in intermediate exchange leading to line broadening, or is 
aggregating and therefore is forming particles that are too large to be visible by NMR 
(Figure 3.9) (gel filtration chromatography indicates the later may be true, data not 
shown). Since our lab has had some success in acquiring good spectral data of 
NaChBac VSD (Voltage-Gated Sodium Channel of Bacillus halodurans VSD) in bicelles 
(unpublished) we tried to use a similar system of NaV1.5 VSD IV-9H in bicelles. We 
mixed NaV1.5 VSD IV-9H in n-DPC micelles with DMPC and dialyzed away the n-DPC 
to form proteoliposomes. We reconstituted the preoteoliposomes into 1:2:1 
DMPC:DHPC:n-DPC bicelles and carried out 15N-TROSY experiments at 25 ℃ and 42 
℃. A great improvement of spectral quality was obtained in bicelles vs micelles (Figure 
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3.10). Although the spectral quality increased, the presence of a higher number of 
peaks than expected indicates the possible presence of conformational heterogeneity. 
One way to confirm and perhaps overcome this is to use toxins known to interact with 
VSD IV of NaV1.5 (such as ATX-II, ApA, and ApB) to lock the VSD into one 
conformational state. 
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Figure 3.9: 15N-TROSY NMR spectroscopy of 15N-NaV1.5 VSD IV-9H. A 15N-TROSY spectrum that 
was run on 270 μM 15N-NaV1.5 VSD IV-9H at 40℃ displays spectral broadening and lack of dispersion, 
indicating that aggregation may be occurring.
Figure 3.8: 15N-TROSY NMR spectroscopy of 15N-NaV1.5 VSD IV-9H. 15N-TROSY spectra was run on 15N-NaV1.5 VSD IV-9H at 40℃ 



















Figure 3.10: 2-D 15N-TROSY spectra of 15N isotopically labeled NaV1.5 VSD IV-9H. 15N-TROSY of 
300 μM NaV1.5 VSD IV-9H in bicelles (blue and red) and n-DPC micelles (black). The bicelle sample 
was run at two different temperatures, 42℃ (red) and 25℃ (blue), while the micelle sample was run at 
40℃. Bicelle samples (colored) show vast improvement in signal compared to the micelle sample 
(black).
Figure 3.9: 2-D 15N-TROSY spectra of 15N isotopically labeled NaV1.5 VSD IV-9H. 15N-TROSY of NaV1.5 VSD IV-9H in bicelles (blue and red) and n-DPC micelles (black). The 
bicelle sample was run at two different temperatures, 42℃ (red) and 25℃ (blue), while the micelle sample was run at 40℃. Bicelle samples (colored) show vast improvement in 



















Structural studies are severely lacking in the realm of mammalian NaVs, and only 
a few structures of bacterial NaVs channels exist to date (32, 33, 34, 106). This is in 
significant part due to the large structure and complexity of mammalian NaVs. One way 
to overcome this problem is to express portions of individual subunits to vastly reduce 
the size and complexity for structural studies by methods such as NMR. Here we have 
shown that we can express a human cardiac voltage-gated sodium channel VSD in a 
bacterial expression system in milligram quantities. This provides us with the ability to 
isotopically label NaV1.5 VSD IV-9H, which is necessary to conduct NMR based 
structural analysis as has been demonstrated for VSDs from KVAP(28) and KCNQ1 
(81). Recombinant protein expression also allowed us to incorporate a 9 residue His-tag 
allowing for IMAC purification. Furthermore, by immobilizing the VSD of interest to a 
metal affinity resin we were able to pull down a potentially novel toxin from the venom of 
G. rosea. The binding of this novel toxin to NaV1.5 VSD IV suggests that it is a site 3 
gating modifier toxin and would most likely inhibit or slow fast inactivation, though more 
studies are needed to confirm this hypothesis. This method of toxin discovery will aid in 
the growing field of venomics and produce lead compounds for drug design targeted 
toward NaVs as seen with CaV inhibitor Ziconitide (107). Furthermore, structural studies 
of these neurotoxins in complex with VSDs may lead to a better understanding of the 
mechanism of action of toxin activity and voltage gating given the fact that these toxins 
bind to VSDs in state specific manners. 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Chapter 4
Chemical and Biological Synthesis of the Human 
Cardiac Sodium Channel Voltage-Sensor Domain IV 
Paddle Motif
Mohammed H. Bhuiyan, Adel K. Hussein, Boris Arshava, Jianqin Zhuang, Fred Naider, 
Sébastien F. Poget 
4.1 Abstract
Voltage-gated sodium channels (NaVs) are membrane proteins that serve 
important functions in the central and peripheral nervous systems (C/PNS) and cardiac 
and skeletal muscle. NaVs participate in the regulation of the membrane potential across 
the plasma membrane of excitable cells and are involved in the depolarization process. 
Currently there are nine subtypes of NaVs that have been characterized to date, Nav1.1 
– Nav1.9. The nine subtypes are expressed in a tissue specific manner, each with 
unique gating properties. Numerous channelopathies have been linked to defects in 
NaVs including epilepsy, mental retardation, and several ailments that could lead to 
sudden heart death. Interestingly, the primary target of peptide toxins from venomous 
and poisonous animals are VGICs, encompassing NaVs. These toxins have been used 
as excellent probes for the identification and functional characterization of NaVs due to 
their specific and potent effect. By solving the structural details of the interaction 
between animal peptide toxins and NaVs we will gain more insight into the function of 
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these channels. However, probing these interactions at the atomic level proves to be 
difficult as NaVs are large (200 kDa), highly hydrophobic, flexible and difficult to purify 
proteins. This makes it unlikely that X-ray crystallography, solution-state NMR or cryo-
EM would be successful. As an alternative strategy to overcome the difficulties NaVs 
pose to us, we will study a common peptide toxin binding motif, the S3b-S4 paddle motif 
in complex with an interacting toxin. The Nav1.5 DIV S3b-S4 paddle motif is a small 
portion of the channel that has been shown to interact with α-scorpion and sea 
anemone toxins, which inhibit the channels’ ability to fast inactivate. We have 
synthesized the paddle motif chemically and biosynthetically through Fmoc solid phase 
peptide synthesis and recombinant expression, respectively. Furthermore, we have 
characterized the paddle motif through circular dichroism, UV spectroscopy and 
solution-state NMR experiments.
4.2 Materials and Methods
4.2.1 Design of NaV1.5 DIV S3-S4 Paddle Motif
Using the sequence alignment tool, T-Coffee (108), the complete S3 and S4 
transmembrane domains and the connecting loop of NaV1.5 DIV, as defined by 
UniProt(109), was aligned with the S3-S4 paddle motif of Nav1.2 VSD IV used by 
Martin-Eauclaire et al. (26) in their SPR experiments. We also modeled the same 
sequence of residues used in our sequence alignment using Swiss-Model (110).
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4.2.2 Chemical Synthesis and Purification of NaV1.5 DIV S3-S4 Paddle Motif
The 37 residue NaV1.5 DIV S3-S4 paddle motif was chemically synthesized 
using 0.1 mMol fast Fmoc solid phase peptide chemistry on a Applied Biosystems 433A 
synthesizer. The synthesis was carried out on the 0.1 mMol scale using Fmoc-Ile Wang 
resin (0.5 mMol/g). The side chain protected amino acids used were Fmoc-Arg(Pmc), 
Fmoc-Thr(tBut), Fmoc-Ser(tBut), Fmoc-Lys(Boc), Fmoc-Gln(Trt), and Fmoc-Asp(OtBu). 
All amino acids were attached using single coupling. Upon completion of the synthesis 
the peptidyl resin was cleaved at room temperature with a cleavage cocktail (95%TFA, 
2.5% H2O, 2.5% Triisopropylsilane) for 105 minutes and filtered. The filtrate was 
concentrated on a rotary evaporator under vacuum and precipitated with cold ehtyl-
ether and dried. The crude peptide was dissolved in 50% TFE and 50% buffer A (H2O, 
0.1% TFA) and purified on an Agilent 1100 series RP-HPLC running a 20-90% gradient 
with increasing buffer B (Acetonitrile, 0.1% TFA) over 60 minutes at 50℃ using a 
preparative Agilent Zorbax 300SB C3 column (21x150 mm) with inverted flow. The final 
yield of the synthesis was 28% of the correct peptide in the crude peptide by RP-HPLC. 
Peptide purity was analyzed by injection onto an Agilent 1100 series RP-HPLC 
equipped with an Eclipse XDB-C8 column with inverted flow, running a gradient of 
20-90% increasing buffer B over 20 minutes at 50 ℃.
4.2.3 Plasmid design of TrpΔLE-NaV1.5 DIV S3-S4 Paddle Motif
The DNA sequence coding for the 37 residue peptide was cloned from 
pNaV1.5DIVsynth using standard PCR techniques with the primers (Fwd: 5’-
GGGAAGCTTTGGATGGTGGTTGTGATCCTGAGCATC-3’ and Rev: 5’-CGGGGATCCTCAGATACGGCCGATGCGG-3’) and 
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purified using the QIAquick PCR Purification Kit (Qiagen). PCR amplified DNA and 
pMMHa(111) obtained from the Naider lab were cleaved with the restriction enzymes 
HindIII (NEB) and BamHI (NEB) following NEB’s recommended conditions for 2 H at 37 
℃. Both DNA products were gel purified using the QIAquick Gel Extraction Kit (Qiagen). 
The digested PCR insert was ligated into the digested pMMHA plasmid in a 3:1 molar 
ratio using Instant Sticky-end Ligase Master Mix (NEB) and transformed into NEB® 5-
alpha competent E. coli (NEB). Plasmid DNA was isolated from 5 ml overnight LB 
cultures of transformed cells using the QIAprep Spin Miniprep Kit (Qiagen) and sent for 
sequencing at GeneWizInc. using a T7 promoter sequencing primer. We performed 
sequence analysis using Serial Cloner (Serial Basics) and confirmed the insertion of the 
NaV1.5 DIV S3-S4 paddle Motif into pMMHa to obtain the plasmid pNaV1.5IVPM.
4.2.4 Biosynthesis and Purification of NaV1.5 DIV S3-S4 Paddle Motif
pNaV1.5IVPM was transformed into the E. coli expression cell strain C43 (DE3). 
M63 minimal media (pH 7) (supplemented with 3g/L of 12C-D-glucose or 13C-D-glucose 
and 1 g/L 14N-NH4Cl or 15N-NH4Cl) was inoculated with 20 mL of overnight LB cultures 
of pNaV1.5IVPM transformed C43 (DE3) and grown at 37 ℃ with shaking at 250 rpm. 
Upon OD600 reaching 0.4, the culture was induced with IPTG (1 mM final concentration) 
and grown for an additional 22 H. Cells were harvested by centrifugation (4 ℃ and 4000 
rpm for 20 minutes). All of the following steps were carried out on ice unless otherwise 
stated. Harvested cells were resuspend in lysis mix (50 mM Tris-HCl (pH 8), 1 mM 
EDTA, 1 mM PMSF, 0.3 mM lysozyme) and sonicated in a cup sonicator and 
centrifuged at 18,000 rpm for 20minutes in an SS-34 rotor. The supernatant was 
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discarded and the pellet was resuspended in lysis buffer (50 mM Tris-HCl (pH 8), 1 mM 
EDTA) by sonication, and centrifuged as stated in the previous step. Once again the 
supernatant was discarded and the pellet resuspended in mild detergent (1% igepal 
Ca-630 and 1% deoxycholic acid in lysis buffer) by sonication and centrifuged. The 
pellet generated after treatment with mild detergent was then resuspended in water to 
remove any residual detergent, and centrifuged. Finally the last pellet was resuspended 
in water and aliquoted into 1 mL fractions and centrifuged for 60 minutes at 14,800 rpm. 
Pellets were stored at -20 °C until needed. Three pellets were dissolved into 1 mL of of 
binding buffer (8 M urea, 500 mM NaCl, 20 mM NaPi (pH 7.3), 2% sarcosine); and 
sonicated to clarify the solution if necessary. The dissolved pellets were then incubated 
with 0.25 mL of Ni Sepharose 6 Fast Flow (GE healthcare) that was pre-equilbrated with 
binding buffer following the manufactures protocol and incubated for 1 hour at room 
temperature with gentle rocking. After incubation, the resin and fusion protein solution 
were transferred to a Poly-Prep Chromatography Column (Bio-Rad), and washed twice 
with 4 column volumes of binding buffer. The fusion protein was then eluted from the 
resin with 4 column volumes of elution buffer (500 mM NaCl, 500 mM imidazole, 20 mM 
NaPi (pH 7.3), 2% sarcosine). The eluted sample was then dialyzed extensively in water 
to induce precipitation and lyophilized. The lyophilized fusion protein was then dissolved 
in 700 μL of 100% TFA by sonication and diluted to 70% TFA with water. The dissolved 
fusion protein was then treated with 100 mg of cyanogen bromide (CNBr) and cleaved 
for 2.5 H at room temperature in the dark. The cleavage mixture was then injected onto 
an Agilent 1100 series RP-HPLC running a 20-90% gradient with increasing buffer B 
(Acetonitrile, 0.1% TFA) over 60 minutes at 50℃ using a preparative Agilent Zorbax 
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300SB C3 column (21x150 mm) with reversed flow direction for purification, and the 
fractions containing NaV1.5 DIV S3-S4 paddle motif were pooled and lyophilized. The 
identity and isotope incorporation of the purified paddle motif were determined by 
MALDI-TOF using a Bruker MicroFlex MALDI-TOF spectrometer. Samples for MALDI-
TOF were prepared following the protocol by Chait’s group(96).
4.2.5 Solution-State NMR of the NaV1.5 DIV S3-S4 Paddle Motif
RP-HPLC purified NaV1.5 DIV S3-S4 paddle motif was dissolved in 10mM 
potassium phosphate (pH 7), 10 mM NaCl, 50 µm DSS, 10% D2O and either 50 mM n-
DPC or Fos-Choline 10 (FC10). All spectral acquisition was carried out at 37 ℃ on a 
Varian Inova 600 MHz NMR spectrometer equipped with a cryogenically cooled HCN 
probe at The College of Staten Island. The unlabeled peptide (14N/12C) was subjected to 
homonuclear 2D-TOCSY and 2D-NOESY at a total peptide concentration of 1 mM. 500 
μM 15N/13C labeled paddle was subjected to HNCO and HN(CO)CA 3D experiments on 
a Bruker AVANCE III HD 800 MHz NMR spectrometer equipped with a 5-mm TCI 
cryoprobe at the CUNY Advanced Science Research Center. HNCA and HNCACB 3D 
experiments were collected on a Bruker AVANCE III HD 700 MHz NMR at the New York 
Structural Biology Center. For toxin interaction studies a 500 μM 15N labeled paddle 
sample was diluted 8-fold and its HSQC spectrum recorded both before and after the 
addition of ApA toxin to a final concentration of 17.3 μM at The College of Staten Island. 
Peptide concentrations were determined by mass, as NaV1.5 DIV S3-S4 paddle motif 
does not contain tryptophan residues. All processing was done with NMRPipe (87) and 
analyzed with CCPNmr Analysis (88).
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4.3 Results and Discussion
4.3.1 Defining the Human Cardiac NaV DIV S3-S4 Paddle Motif
We used the NaV1.2 DIV S3-S4 paddle motif used by Martin-Eauclaire et al.(40) 
in their elegant surface plasmon resonance studies as template for sequence alignment 
of the NaV1.5 S3-loop-S4 sequence. This choice was based on the fact that Martin-
Eauclaire et al. showed that their 32 residue peptide is sufficient for binding of site 3 
gating modifier toxins in SPR experiments. We aligned our S3-loop-S4 sequence 
fragment as defined by UniProt (109) with the Martin-Eauclaire et al. peptide using the 
software T-Coffee (108). The T-Coffee sequence alignment shows good agreement 
between the two sequences due to the high homology between the two paddle motifs 
(Figure 4.1). The results from Swiss-Model (110) modeling of the S3-loop-S4 fragment 
showed that this sequence is likely to adopt a helix loop helix hairpin motif, helping us to 
further refine the final sequence we used for all further experiments (Figure 4.2) Based 
on the alignment and modeling data we decided to include 5 more residues to the N-
terminus of the NaV1.5 DIV S3-S4 paddle motif compared to the NaV1.2 DIV S3-S4 
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Figure 4.1: Sequence alignment of paddle motifs of neuronal and cardiac NaV. The 32 residue 
NaV1.2 DIV S3-S4 paddle motif shown to bind site 3 toxins aligned with NaV1.5 DIV S3 transmembrane 
domain - extracellular loop - S4 transmembrane domain. Alignment show good homology. “*” 
representing identical residues, “:” representing residues of the same hydropathy and size, and “.” 
representing similar size or hydropathy.
paddle motif to help stabilize the 
peptide in a helix loop helix 
hai rp in mot i f conformat ion, 
therefore the resulting peptide 
consists of 37 residues from 
Valine1597 to Isoleucine1634 out 
of the full 2016 residue NaV1.5 
protein. 
4.3.2 Purification of a Chemically Synthesized Isolated Human Cardiac NaV S3-S4 
         Paddle Motif
We chemically synthesized NaV1.5 DIV S3-S4 paddle motif using standard Fmoc 
solid phase peptide synthesis and the major product was found to be the correct peptide 
(Figure 4.3A). The unlabeled peptide was purified to 98% purity by RP-HPLC (Figure 
4.3B) NaV1.5 DIV S3-S4 paddle motif elutes at 72.5% buffer B (acetonitrile) indicating it 
has a high hydrophobic character. Maldi-TOF analysis confirmed the correct peptide 
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Figure 4.2: Model of An Isolated Human Cardiac NaV S3-
S4 Paddle Motif. The 56 residues coding for NaV1.5 DIV’s S3 
transmembrane domain - extracel lular loop - S4 
transmembrane domain was model by Swiss-Model using 
PDB structure 3LUT as a template. Here we show only the 37 
residues used for all subsequent experiments. Gating 
Arginines shown in blue.
was obtained based on an expected mass of 4204.1 Da ([M]) and an observed a mass 
of 4205.1 Da ([M+H+]) (Figure 4.4).
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Figure 4.3: RP-HPLC Analysis of crude and purified NaV1.5 DIV S3-S4 paddle motif. (A) Analysis of 
crude NaV1.5 DIV S3-S4 paddle motif on an Agilent 1100 series HPLC running 20-90% buffer B at 50℃ 
over 20 minutes eluting at 72.5% buffer B showing 29% purity and indicating it is the major product. (B) 
Analysis of purified NaV1.5 DIV S3-S4 paddle motif indicating 98% purity was obtained after preparative 
RP-HPLC purification.
Data File C:\HPCHEM\1\DATA\BORIS\08241500.D Sample Name: Nav1.5 D4S3S4Lin 
Instrument 1 8/24/2015 4:25:28 PM Boris 
 
Nav1.5 D4 S3-S4-Linker crude peptide 1/2 cleaved, -> 285 mg. in 50% TFE/water+, 10ul 




Injection Date  : 8/24/2015 3:58:40 PM          
Sample Name    : Nav1.5 D S3S4Lin                 
Acq. Operator   : Boris                         
Acq. Method     : C:\HPCHEM\1\METHODS\2090I20.M 
Last changed    : 8/24/2015 3:59:08 PM by Boris 
Analysis Method : C:\HPCHEM\1\METHODS\2090I20.M 
Last changed    : 8/24/2015 4:24:59 PM by Boris 
20-90% at 20min 1 ml/min ACN gradient, +40oC 220nm 
 
===================================================================== 
                         Area Percent Report                          
===================================================================== 
 
Signal 1: VWD1 A, Wavelength=220 nm 
 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]  mAU   *s   [mAU   ]       % 
----|-------|----|-------|----------|----------|--------| 
   1  11.109 MM    1.6047 3163.74170   32.85927  26.3269 
   2  14.750 VV    0.1521  256.80585   25.25955   2.1370 
   3  15.003 VV    0.2012 3532.34375  261.69214  29.3941 
   4  15.514 VV    0.2118 1584.13062  109.94073  13.1822 
   5  15.785 VV    0.1992  646.56769   45.92115   5.3804 
   6  16.154 VV    0.2740  675.42072   33.77987   5.6205 
   7  16.726 VV    0.2696  965.07324   51.15213   8.0308 
   8  23.096 PBA   1.4443 1193.08301   10.04220   9.9282 
Totals :                  1.20172e4   570.64704 
 
===================================================================== 
                          *** End of Report *** 













































Data File C:\HPCHEM\1\DATA\BORIS\08241516.D Sample Name: Nav1.5 D4S3S4Lin 
Instrument 1 8/26/2015 6:22:42 PM Boris 
 
Nav1.5 D4 S3-S4-Linker. Prep HPLC run #1+2 27 mg pooled pure fractions 10ul injected. 




Injection Date  : 8/26/2015 6:01:47 PM          
Sample Name     : Nav1.5 D4S3S4Lin                 
Acq. Operator   : Boris                         
Acq. Method     : C:\HPCHEM\1\METHODS\2090I20.M 
Last changed    : 8/26/2015 6:00:16 PM by Boris 
Analysis Method : C:\HPCHEM\1\METHODS\2090I20.M 
Last changed    : 8/26/2015 6:22:22 PM by Boris 
20-90% at 20min 1 ml/min  ACN gradient, +40oC 220nm 
 
===================================================================== 
                         Area Percent Report                          
===================================================================== 
 
Sorted By             :      Signal 
Multiplier            :      1.0000 
Dilution              :      1.0000 
Use Multiplier & ilution Factor with ISTDs 
 
 
Signal 1: VWD1 A, Wavelength=220 nm 
 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]  mAU   *s   [mAU   ]       % 
----|-------|----|-------|----------|----------|--------| 
   1  14.798 MF    0.0806   28.00762    5.78846   1.1563 
   2  14.967 FM    0.2181 2394.13306  182.97887  98.8437 
Totals :                  2422.14067  188.76733 
 
===================================================================== 
                          *** End of Report *** 
































Figure 4.4: MALDI-TOF Analysis of crude and purified NaV1.5 DIV S3-S4 paddle motif. NaV1.5 DIV 
S3-S4 paddle motif was mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA) 
saturated in either formic acid: water: isopropanol (3:1:2) or acetonitrile (0.1% trifluoroacetic acid): water 
(0.1% trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of NaV1.5 DIV S3-S4 paddle motif is 
4204.1 Da, observed mass is 4205.1 Da.
4.3.3 Biosynthesis and Purification of An Isolated Human Cardiac NaV S3-S4 
         Paddle Motif
Due to the inherently large concentration of detergent molecules in micelles 
(FC10 and n-DPC) that would hinder future structural studies by homonuclear NMR, we 
moved forward in isotopically labeling NaV1.5 DIV S3-S4 paddle motif through bacterial 
expression. We cloned the paddle motif using our synthetic VSD gene 
pNaV1.5VSDIVsynth-NH, as a template into the plasmid pMMHa (111) using standard 
molecular biology techniques. This plasmid has been shown in the past to direct 
membrane protein fragments into inclusion bodies due to the TrpΔLE fusion protein 
fragment (112-114). Since NaV1.5 DIV S3-S4 paddle motif does not code for any 
endogenous Methionine residues, expression as a TrpΔLE fusion protein is suitable for 
CNBr cleavage from TrpΔLE without the incorporation of non-endogenous residues. 
Expression of the TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein was carried out 
in M63 minimal media (containing isotopically enriched 15NH4Cl and 13C glucose) in the 
expression cell strain C43 (DE3) at 37 ℃ for 22 H post induction with 1 mM IPTG. 
Inclusion bodies were isolated as was done in (113). We tried to clean up the inclusion 
bodies by batch-wise IMAC purification through the TrpΔLE’s hexa-Histidine tag, but 
this did not significantly improve the purity of the TrpΔLE-NaV1.5 DIV S3-S4 paddle 
motif as multiple protein bands can be seen co-eluting with it by SDS-PAGE analysis 
(Figure 4.5). Fractions containing the TrpΔLE-NaV1.5 DIV S3-S4 paddle motif were 
dialyzed extensively to remove any salts and detergent and lyophilized. TrpΔLE-NaV1.5 
DIV S3-S4 paddle motif was then solubilized in 70% TFA and reacted with CNBr to 
cleave the peptide from the fusion protein, and subjected to RP-HPLC (Figure 4.6). 
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Although CNBr cleavage in TFA was of low efficiency, attempts to optimize in formic 
acid showed similar results. The isotopically double labeled (15N/13C) paddle was 


































Figure 4.5: Purification and SDS-PAGE analysis of TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion 
protein. TrpΔLE-NaV1.5 DIV S3-S4 paddle motif fusion protein was subjected to batch-wise IMAC 
purification using Ni+2-NTA resin where the majority of the protein elutes at a imidazole concentration of 










































































































































































































































































































































































































4.3.4 Structural Studies of the Human Cardiac NaV1.5 DIV S3-S4 Paddle Motif
Initially we dissolved NaV1.5 DIV S3-S4 paddle motif in NMR buffer (10 mM KPi 
10 mM NaCl, 50 µM DSS) containing 50 mM or 100 mM n-DPC for initial TOCSY and 
NOESY experiments based on the successful extraction of the entire NaV1.5 VSD IV-9H 
from E. coli membranes by n-DPC. The spectral quality of the peptide in 50 mM and 
100 mM n-DPC left much to be desired as little signal was obtained. This could be due 
to the fact of n-DPC’s large aggregation number of 54 molecules per empty micelle, 
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Figure 4.7: MALDI-TOF Analysis of purified NaV1.5 DIV S3-S4 paddle motif. NaV1.5 DIV S3-S4 
paddle motif was mixed and crystalized with α-Cyano-4-hydroxycinnamic acid (4-HCCA) saturated in 
either formic acid: water: isopropanol (3:1:2) or acetonitrile (0.1% trifluoroacetic acid): water (0.1% 
trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of 15N/13C-NaV1.5 DIV S3-S4 paddle motif is 
4454.1 Da, observed mass is 4412.6 Da showing an isotope incorporation of 83.1%.
leading to slower tumbling of the petidyl-micellular complex and increased line 
broadening. Therefore, we investigated using FC-10, which retains the head group of n-
DPC, but with a smaller alkyl chain of 10, and a much smaller aggregation number of 
24. 2D homonuclear TOCSY and NOESY experiments were then performed on the 
peptide in 50 mM FC10, which yielded marked improvement in spectral quality (Figure 
4.8). Though FC10 showed promise, it also had drawbacks, due to the high 
concentration of detergent molecules it produced large signal in the aliphatic region, 
making side chain assignments of NaV1.5 DIV S3-S4 paddle motif impractical (Figure 
4.8). Since deuterated n-DPC is not readily available (as a custom synthesis was 
quoted at $15,000), we decided to isotopically label the peptide (Figure 4.9) and utilize 
standard 2D- and 3D-heteronuclear techniques to make backbone assignments. The 
2D- 15N-HSQC shows good spectral dispersion indicating the peptide is well behaved 
and folded (as corroborated with CD analysis showing one maximum at 190 nm and two 
minima at 208 nm and 220 nm, which is characteristic of α-helical peptides/proteins 
(Figure 4.9)) (Figure 4.10). We then proceeded to run all the necessary triple resonance 
experiments for backbone assignments, HNCO, HNCA, HNCOCA, and HNCACB. We 
were able to assign 86% of the theoretically observable residues (Table 4.1) using an 
HNCOCA/HNCA walk (Figure 4.11) and confirming connectivities with the aid of the 
HNCACB. Chemical shift index analysis of NaV1.5 DIV S3-S4 paddle motif’s C, Cα, and 
Cβ chemical shifts predict two α-helical regions (Figure 4.12), corroborating both the 
predicted S3 and S4 transmembrane domains defined by Uniprot and the α-helical 
character predicted by CD analysis.
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Figure 4.8 2-D Homonuclear TOCSY spectra of NaV1.5 DIV S3-S4 paddle motif. Fingerprint region 
of 1 mM NaV1.5 DIV S3-S4 paddle motif shown in (A) 50mM n-DPC (blue), (B) 100mM n-DPC (black), 
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Figure 4.9: Circular Dichroism (CD) of NaV1.5 DIV S3-S4 paddle motif. CD analysis of the NaV1.5 
DIV S3-S4 paddle motif in n-DPC (grey) and FC10 (blue) show a maxima at 190nm and two minima at 





Figure 4.10 2-D 15N-HSQC spectra of 15N/13C isotopically labeled NaV1.5 DIV S3-S4 paddle motif. 
HSQC shows a well dispersed peptide indicating the protein may be adopting a folded conformation. Of 
the 36 observable amide protons (proline doesn't have an observable amide proton), 31 correlations are 




















H N C Cα Cβ
Val 1
Val 2 176.77
Val 3 8.47 123.16 177.21 61.78 29.25
Ile 4 8.01 121.30 1 77.19 60.65 35.18
Leu 5 8.25 120.53 178.48 55.09 38.86
Ser 6 8.03 113.80 176.34 58.65 60.15
Ile 7 7.75 121.27 177.50 61.39 35.84
Val 8 8.06 118.22 177.30 63.20 29.06
Gly 9 8.51 106.81 175.13 44.82
Thr 10 7.94 116.51 176.13 63.41 66.54
Val 11 8.01 120.88 177.87 63.19 29.18
Leu 12 8.32 118.43 178.25 55.06 39.24
Ser 13 8.10 113.15 176.32 59.55 60.37
Asp 14 7.91 120.77 178.58 55.01 38.60
Ile 15 8.00 118.88 177.87 62.33 35.52
Ile 16 8.42 119.35 177.56 62.53 34.60
Gln 17 8.06 116.48 177.51 56.64 26.65
Lys 18 7.79 116.60 177.87 56.11 30.63
Tyr 19 7.91 114.82 175.91 56.66 36.97
Phe 20 7.96 117.49 174.56 56.57
Phe 21 7.79 116.44 175.37 55.05
Ser 22 7.55 116.99 53.68 61.36
Pro 23
Thr 24 175.62
Leu 25 7.69 121.53 178.04 55.45 38.79
Phe 26 7.81 116.46 177.30 58.17
Arg 27 7.84 118.48 178.23 56.77
Val 28 7.85 117.88 177.20 63.66 28.91
Ile 29 7.97 118.62 177.30 62.15 34.85
Arg 30 7.84 118.49 178.49 56.69 27.40
Leu 31 7.91 119.25 178.31 54.56 39.33
Ala 32 8.06 120.14 177.80 51.23 16.13
Arg 33 7.89 114.80 176.91 54.73 27.69
Ile 34 7.83 117.13 176.79 59.40 35.96
Gly 35 8.29 110.41 173.49 42.95
Arg 36 7.96 119.20 174.76 53.21 28.60
Ile 37 7.60 124.45 60.26 37.06
Table 4.1: Chemical shift assignments of NaV1.5 DIV S3-S4 paddle motif  (in ppm)
H N C α Cβ
Val 1
Val 2 176.77
Val 3 8.47 23.16 177.21 61.78 29.25
Ile 4 8.0 121.30 1 77.19 60.65 35.18
Leu 8.25 20.53 178.48 55.09 38.86
Ser 6 8.03 13.80 176.34 58.6 60.15
Ile 7 7.75 21.27 177.50 61.39 35.84
Val 8 .06 18.22 177.3 63.20 29.06
Gly 9 8.5 06.81 175.13 44.82
Thr 10 7.94 1 .51 176.13 3.41 66.54
Val 1 8 01 20 8 177 87 63 9 29.18
Leu 1 32 1 43 178 25 55 06 39.24
Ser 3 8 0 13 15 176 32 59 55 60.37
Asp 14 7 91 20 77 178 58 55 01 38.60
Ile 15 00 18 8 177 87 62 33 35.52
Ile 16 8 42 19 35 177 6 62 53 34.60
Gln 17 8 06 16 48 177 51 5 4 26.65
Lys 18 7 79 16 60 177.87 56 11 30.63
Tyr 19 7 91 14 82 175 91 5 66 36.97
Phe 20 96 17 49 174 6 56.57
Phe 21 7 79 16 44 17 37 55.05
Ser 22 7 55 116.99 53 68 61.36
Pro 23
Thr 24 175.62
Leu 25 7 69 21 53 178 04 55 45 38.79
Phe 26 7 81 16 46 177 30 58.17
Arg 27 7 84 1 48 178 23 56.77
Val 28 5 1 88 177 20 63 66 28.91
Ile 29 7 97 18 62 177 30 62 1 34.85
Arg 30 7 84 1 178 4 56 69 27.40
Leu 3 7 91 19 25 178 31 54 56 39.33
Ala 32 8 06 20 14 177 80 51 2 16.13
Arg 33 7 9 14 80 176 91 54 73 27.69
Ile 34 8 17 13 176 79 59 40 35.96
Gly 35 8 29 10 1 173 49 42.95
Arg 3 7 96 19 20 174 76 53 21 28.60
Ile 37 7 60 124 45 60 2 37.06











































































































































































































































































































































































4.3.5 Interactions of the Human Cardiac NaV1.5 DIV S3-S4 Paddle Motif
Upon assignment of the NaV1.5 DIV S3-S4 paddle motif we wanted to probe the 
structural interactions in the presence of a gating-modifier. We selected the sea 
anemone gating-modifier toxin ApA as it is a known site 3 toxin(65) and our lab has the 
ability to biosynthesize and correctly fold this toxin (though not in great yields). We 
recorded the 15N-HSQC of an 8-fold diluted sample in the presence and absence of the 
gating-modifier toxin ApA. Although the diluted sample yielded a weak signal most of the 
peaks were still present, but interestingly upon the addition of toxin the signal was 
absent (Figure 4.13). To determine what was the cause of the lack of signal we took the 
NMR sample of the paddle in the presence of toxin and carried out MALDI-TOF and UV-
Vis spectroscopy to determine if the paddle was still present and it concentration. 
MALDI-TOF analysis indicated that upon the addition of ApA the paddle remained in 
solution (Figure 4.14) and UV-Vis indicated a paddle peptide concentration of ~117 μM 
(though this may not be accurate as NaV1.5 DIV S3-S4 paddle motif does not contain a 
Tryptophan residue). Based on both the MALDI-TOF and UV-Vis spectroscopy data 
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Figure 4.12: Chemical shift index of NaV1.5 DIV S3-S4 paddle motif. Chemical shift index of C’, Cα 
and Cβ predict two α-helical regions where UniProt predicts the two transmembrane helices S3 and S4 
(green boxes).
d α N (d αδ )
d N N (d N δ ,d δ N )
d β N (d βδ )
d α N (i,i+3)
d α β (i,i+3)
d α N (i,i+4)
d N N (i,i+2)
d α N (i,i+2)
∆δ( 13 C α )
∆δ( 13 C β )
∆δ( 13 C' )
∆δ( 1 H α )
V V V I L S I V G
10
T V L S D I I Q K Y
20
F F S P T L F R V I
30
R L A R I G R I
d α N (d αδ )
d N N (d N δ ,d δ N )
d β N (d βδ )
d α N (i,i+3)
d α β (i,i+3)
d α N (i,i+4)
d N N (i,i+2)
d α N (i,i+2)
∆δ( 13 C α )
∆δ( 13 C β )
∆δ( 13 C' )
∆δ( 1 H α )
V V V I L S I V G
10
T V L S D I I Q K Y
20
F F S P T L F R V I
30
R L A R I G R I
Figure 4.12: Chemical shift index of NaV1.5 DIV S3-S4 paddle motif. Chemical shift index of C’, Cα 
and Cβ predict two α-helical regions where UniProt predicts the two transmembrane helices S3 and 
S4 (green boxes).
indicating the paddle and toxin remained in solution points to the lack of signal in the 













































































Figure 4.12 2-D 15N-HSQC spectra of 15N isotopically labeled NaV1.5 DIV S3-S4 paddle motif in the absence and presence 
of ApA. HSQC shows a well dispersed peptide indicating the protein may be taking a fold. Of the 36 observable Amide protons 




Figure 4.13 2-D 15N-HSQC spectra of 15N isotopically labeled NaV1.5 DIV S3-S4 paddle motif in the 
absence and presence of ApA. HSQC spectra of (A) non-diluted 500 μM 15N/13C isotopically labeled 
peptide in 50 mM FC10 s mple in the absence of ApA, (B) 500 μM 15N i otopically labeled peptide in 50 
mM FC10 sample diluted 8-fold in the absence of ApA, and (C) 500 μM 15N isotopically labeled peptide 
in 50 mM FC10 sample diluted 8-fold in the presence of 17.3 μM ApA showing complete loss of signal 
indicating an interaction.
hydrophobic portions the NaV1.5 DIV S3-S4 paddle motif causing the peptides to form 
large soluble aggregates that may be invisible to solution-state NMR.
4.4 Conclusions
As of this writing, there have been no structural studies of isolated mammalian 
NaV paddle motifs and only one structurally characterized isolated KV paddle motif 
(115). Moreover, previous research has indicated that transplanted and isolated paddle 
motifs retain sufficient information to recognize and bind toxins (26, 40). Here we 
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Figure 4.14: MALDI-TOF Analysis of 15N-NaV1.5 DIV S3-S4 paddle motif NMR sample in the 
presence of ApA. The paddle-toxin NMR sample was mixed and crystalized with α-Cyano-4-
hydroxycinnamic acid (4-HCCA) saturated in acetonitrile (0.1% trifluoroacetic acid): water (0.1% 
trifluoroacetic acid) (2:1) in a 1:9 ratio. The expected mass of 15N-NaV1.5 DIV S3-S4 paddle motif is 
4255.1 Da, observed mass is 4255.3 Da, and the expected mass of ApA is 5131.7, observed mass is 
5132.3.
sodium channel. We were able to biosynthesize the NaV1.5 DIV S3-S4 paddle motif of 
DIV in isotopically labeled form in E. coli, allowing us to make back bone assignments to 
86% completion. The HSQC indicates that the NaV1.5 DIV S3-S4 paddle motif is a well 
behaved structured peptide, although upon addition of a site 3 getting-modifier toxin 
(ApA) known to interact with NaV1.5 the HSQC signal is undetectable. MALDI-TOF and 
UV-Vis spectroscopy indicated the paddle and toxin remained in solution, supporting the 
hypothesis that lack of signal in the NMR experiment is due to an interaction between 
the two. We can perform isothermal calorimetry (ITC) or SPR to study the interaction 
between the two peptides and derive the KD. If we hope to structurally characterize the 
interaction we need overcome this lack of NMR signal. Experiments such as gel 
filtration chromatography and multi angle light scattering will give insights to the both the 
molecular weight and size (respectively) of the NaV1.5 DIV S3-S4 paddle motif before 
and after treatment with ApA. If ApA is causing soluble aggregates invisible to solution-
state NMR, solid-state NMR could be an alternative probing the interactions. NMR 
conditions (salt, pH, temperature) could also be adjusted in an effort to improve 
solution-state signal acquisition. Also based on the SPR studies done with the NaV1.2 
DIV S3-S4 paddle motif by Martin-Eauclaire et al.(40) one could further this concept by 
immobilizing the paddle motifs on a resin to perform affinity chromatography on various 
venoms to aid in toxin discovery specifically site 3 gating-modifier toxins. In addition, 
utilization of our chemical shift assignments of NaV1.5 DIV S3-S4 paddle motif will allow 
for the rapid elucidation of structural interactions initiated by various site 3 toxins 
(including novel toxins) that target NaV1.5 (provided that the signal does not disappear).
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Chapter 5
Concluding Remarks and Future Directions
Peptide neurotoxins are believed to hold the secret to treating many 
channelopathies owing to their high affinity (dissociation constant typically in the nM 
range) and NaV isoform selectivity. Here we have presented the ground work to 
extracting and possibly exploiting interactions governing the strong and specific binding 
between peptide neurotoxins and their cognate receptors. Firstly we solved the first 3D 
structure of a teretoxin, Tv1 (79). Tv1 has been shown to possess biological activity 
when tested on polychaete worms although its molecular target remains to be 
determined. One possible way to determine its cognate receptor is to immobilize Tv1 on 
a resin and treat this resin with polychaete lysate in an effort to pull down, enrich, and 
possibly identify the target through mass spectrometry sequencing. Although its cognate 
receptor remains elusive, once discovered and purified, various molecular biological, 
specifically site-directed mutagenesis, and biophysical methods such as NMR 
spectroscopy (titration and cross saturation), mass spectrometry, and drug design/
modeling experiments can be carried out to determine the modes of interaction. Binding 
assays such as SPR and ITC can be used to determine binding affinities. Also once the 
molecular target of Tv1 is known peptide engineering can ensue much as was done 
with ProToxin II by Park et al (116). ProToxin-II was mutated at various locations within 
the peptide with and without truncation, modification, or addition to the C-terminal tail to 
increase toxin affinity to both NaV1.7 and NaV1.2 (116). Engineering of known peptide 
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neurotoxins can increase affinity, and increase isoform specificity, thereby decreasing 
the amount of toxin necessary (lowering the cost to manufacture) and lessening the 
side-effects. 
Secondly, VSDs are responsible for the three functional states (open, closed, and 
inactivated) of VGICs, and to date there has been no structural characterization of a 
eukaryotic VSD. Even though there has been structural characterization from VSDs of 
KVs (in isolation and full channels) (28-31) and bacterial NaVs (full channels) (32, 33, 
34), these VSDs are identical in each of the four domains of their respective 
homotetrameric channels, where as in eukaryotic NaVs the channel is formed by 
pseudotetrameric domains which contain differences in sequence and therefore behave 
kinetically different. Here we have demonstrated the bacterial expression of an isolated 
VSD of a eukaryotic NaV, specifically VSD IV of the human cardiac sodium channel 
NaV1.5. We have isotopically labeled this VSD, used it to pull down spider peptide 
neurotoxins, and placed the VSD in isotropic bicelles. The work of chapter 3 lays the 
foundation for performing 3D heteronuclear experiments and making backbone 
assignments of a NaV VSD. Although our studies of VSD IV of NaV1.5 show 
conformational heterogeneity, locking the VSD into one conformation with the aid of a 
site 3 neurotoxin may reduce the conformational heterogeneity, improving spectral 
quality leading to the possibility of recording high quality spectral data. Our lab has 
synthesized the sea anemone toxin ApA with some success, therefore this hypothesis 
can be tested in the future with 15N-TROSY titration experiments. If titration experiments 
of NaV1.5 VSD IV with ApA prove successful we can test the feasibility of 3D NMR 
backbone experiments (HNCO, HNCA, HNCOCA…) in a similar way to what we have 
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done with NaV1.5 DIV S3-S4 paddle motif. This would provide the first backbone 
assignments of a mammalian NaV VSD. 
Paddle motifs are the recognition site of the gating-modifier toxins (8), and 
although this is the recognition site of two important classes of toxins (site 3 and 4 
toxins), the interaction between the two is not well characterized on the atomistic level. 
To address this lack of information, we have synthesized and expressed the paddle 
motif from VSD IV of NaV1.5. We expected that the paddle motif of NaV1.5 DIV would 
take a similar fold to the already solved structure of the paddle motif from the HsapBK 
K+ channel in n-DPC micelles (115). CD analysis of a NaV1.5 DIV S3-S4 paddle motif 
suggests that it has α-helical character as seen from the structure of the HsapBK K+ 
channel paddle motif. We have run all of the necessary 2D and 3D heteronuclear 
experiments to obtain backbone assignments for the paddle motif peptide. With these 
as a foundation we can begin experiments such as 15N-edited NOESY-HSQC to derive 
the 3D fold to produce the first recorded three dimensional structure of a mammalian 
NaV paddle motif. Running of sophisticated titration and cross saturation NMR 
experiments will begin to unravel, with atomic precision, the residues and key 
interactions involved in peptide neurotoxin/NaV paddle motif interaction, recognition, and 
binding. Such studies have been initiated with our studies on the interaction of ApA and 
NaV1.5 DIV S3-S4 paddle motif. Taken as a whole, the work presented in this 
dissertation provides several avenues for continued investigation that should result into 
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Samples were prepared in 1:2 volume ratio of sample:sample buffer.
Samples were then sonicated in a low powered bath sonicator for 5 minutes.
Samples were then heated for 3-5minutes at 95℃ (membrane protein samples were 
not boiled).
Samples were then loaded on to either Any kD™ Mini-PROTEAN® TGX™ Precast 
Protein Gels (Bio-Rad) or home poured 15% poly-acrylamide gels.
Gels were run at 120 V until protein marker reached resolving gel and began separation 
at which voltage was increased to 180 V.
Gels were then stained either stained with Pierce™ Silver Stain Kit (Thermo Fisher 
Scientific Inc.) or 0.1% Coomassie Brilliant Blue in 40% methanol, 10% acetic acid.
All Recipes can be found in the Mini-PROTEAN® Tetra Cell Instruction Manual (Bio-
Rad) 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A3 Western Blot Analysis
Protein gels were incubated in transfer buffer for 15 minutes, as was nitrocellulose 
membrane and blotting paper (protein gels separate from nitrocellulose membranes and 
blotting paper).
Transfer of protein from protein gels to nitrocellulose paper was carried out using a Bio-
Rad Trans-Blot® SD Semi-Dry Transfer Cell at 15 V for 20 minutes.
Nitrocellulose membranes were then treated with blocking buffer (TBST+ 0.1% BSA) for 
1 hour at room temperature or 4℃ overnight.
Nitrocellulose membranes were then treated with 1° mouse anti-6XHis antibody for 1 
hour at room temperature in blocking buffer. (1:3000 dilution)
Nitrocellulose membranes are then washed 1X for 15 minutes with TBST and 3X for 5  
minutes with TBST
Nitrocellulose membranes are then treated with 2° goat anti-mouse HRP antibody in 
blocking buffer for 1 hour at room temperature. (1:3000 dilution)
Nitrocellulose membranes are then washed 1X for 15 minutes with TBST and 3X for 5  
minutes with TBST.
Nitrocellulose was then treated with SuperSignal™ West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific Inc.) following the manufacturers protocol and 
imaged.
Transfer Buffer: 25 mM Tris, 192 mM glycine, 0.3 % SDS, 25 % methanol
10X TBS: 200 mM TRIS (pH7.4), 1.5 M NaCl
TBST: 1X TBS + 0.05% Tween-20  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A4 M63 Growth Medium
M63 Buffer:
For 1 L of growth medium:
Add 13.6 g KH2PO4, 4 g KOH, 100 μL FeSO4 stock (500 mg FeSO4*7H2O + 100 ml 0.01N HCl) and 0.5 
-1.0 g 14/15NH4Cl to 900 mL H2O, check pH and adjust if necessary, autoclave.
Autoclave 6 g (2-14 g) glucose in 100 mL H2O separately.
Before inoculation, combine M63 medium and glucose and add:
1 mL vitamin mix
1 mL Mg solution
5 mL solution C
Antibiotic
Supplements
Mg solution: 1M stock. 24.6 gm MgSO4*7H2O / 100 ml. 
Autoclave separately. 
Vitamin mix (for 50 mL, filter-sterilize and store at 4 °C, wrapped in foil):
nicotinic acid 100 mg
thiamin * HCl   50 mg
para-aminobenzoic acid   10 mg
biotin     1 mg
Solution C stock: (mineral solution for growth in minimal media, filter sterilize and store at 4 °C)
Per Liter:
Nitrilotriacetic acid (wear gloves)10.0 g
MgCl2 * 6H2O 24.0 g
CaCl2 * 2H2O 3.335 g
Metals 44 (see below) 50 mL
KOH 7.3 gm
Dissolve KOH in ~ 500 mL of ddH2O. Add NTA, dissolve, then add the remaining ingredients and adjust to 
pH 6.7-6.8 with 5M and 1M KOH (~8.5 mL of 5M KOH). Allow any precipitate to dissolve between 
additions of KOH. As the precipitate dissolves, the pH changes (takes a while to adjust pH).




FeCl2 * 4H2O 5.02
MnCl2 * 4H2O 1.8
(NH4)6Mo7O24 * 4H2O 0.185
CuCl2 * 2H2O 0.156
Co(NO3)2 * 6H2O 0.248
Boric acid 0.144
Mix chemicals in ~500 mL ddH2O. After dissolved, bring volume to 1.0 L. pH will be ~ 4. The 
solution will appear green, and will oxidize over time and turn yellowish. 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